Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Workshops and Meetings
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Disease Models & Mechanisms
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Disease Models & Mechanisms

Advanced search

RSS   Twitter   Facebook   YouTube

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Workshops and Meetings
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
Review
Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells
Dido Carrero, Clara Soria-Valles, Carlos López-Otín
Disease Models & Mechanisms 2016 9: 719-735; doi: 10.1242/dmm.024711
Dido Carrero
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo 33006, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dido Carrero
Clara Soria-Valles
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo 33006, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Clara Soria-Valles
Carlos López-Otín
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo 33006, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: clo@uniovi.es
  • Article
  • Figures & tables
  • Info & metrics
  • PDF
Loading

ABSTRACT

Ageing is a process that inevitably affects most living organisms and involves the accumulation of macromolecular damage, genomic instability and loss of heterochromatin. Together, these alterations lead to a decline in stem cell function and to a reduced capability to regenerate tissue. In recent years, several genetic pathways and biochemical mechanisms that contribute to physiological ageing have been described, but further research is needed to better characterize this complex biological process. Because premature ageing (progeroid) syndromes, including progeria, mimic many of the characteristics of human ageing, research into these conditions has proven to be very useful not only to identify the underlying causal mechanisms and identify treatments for these pathologies, but also for the study of physiological ageing. In this Review, we summarize the main cellular and animal models used in progeria research, with an emphasis on patient-derived induced pluripotent stem cell models, and define a series of molecular and cellular hallmarks that characterize progeroid syndromes and parallel physiological ageing. Finally, we describe the therapeutic strategies being investigated for the treatment of progeroid syndromes, and their main limitations.

Introduction

The physiological deterioration that accompanies ageing constitutes a major risk factor for the development of human pathologies, such as cancer, cardiovascular disorders and neurodegenerative diseases (Kennedy et al., 2014). Key molecular hallmarks of the ageing phenotype include telomere attrition, genomic instability, loss of proteostasis, epigenetic alterations, mitochondrial dysfunction, deregulated nutrient sensing, stem cell exhaustion, cellular senescence and altered intercellular communication (Lopez-Otin et al., 2013). At the macromolecular level, ageing is characterized by the development of wrinkles, greying and loss of hair, presbyopia, osteoarthritis and osteoporosis, progressive loss of fertility, loss of muscle mass and mobility, decreased cognitive ability, hearing loss, and a higher risk for the development of cancer and heart diseases, among other features (López-Otín et al., 2013).

Progeroid syndromes are a group of very rare genetic disorders that are characterized by clinical features that mimic physiological ageing, such as hair loss, short stature, skin tightness, cardiovascular diseases and osteoporosis. Consequently, they constitute a relevant source of information to understand the molecular mechanisms involved in normal ageing. Progeroid disorders do not show differences in prevalence depending on sex or ethnic origin, and appear at an early age, mainly due to defects in the nuclear envelope and DNA repair mechanisms (Gordon et al., 2014). Affected individuals die at a young age, usually as a consequence of cardiovascular problems and musculoskeletal degeneration.

In this Review, we classify human progeroid syndromes into two main groups according to the mechanisms that underlie the disease. Next, we discuss recent findings in the study of progeroid syndromes, achieved through the use of cellular and animal models. On the basis of these findings, we propose nine candidate hallmarks of premature ageing, and highlight their similarities with those described for physiological ageing. These proposed hallmarks recapitulate the most remarkable characteristics of progeroid syndromes and define the mechanisms underlying their pathogenesis, which could provide ideas for future studies on both physiological and pathological ageing. Finally, we review different therapeutic strategies developed for the treatment of these rare but devastating diseases.

A classification system for human progeroid syndromes

All progeroid syndromes are characterized by similar clinical features (Table 1), but their underlying mechanisms can vary depending on the mutated gene and the pathway that is consequently altered. Below, we have classified progeroid syndromes into two general categories based on the molecular pathway involved. The first group includes those syndromes caused by alterations in components of the nuclear envelope, such as Hutchinson-Gilford progeria syndrome (HGPS), Néstor-Guillermo progeria syndrome (NGPS), atypical progeria syndromes (APSs), restrictive dermopathy (RD) and mandibuloacral dysplasia (MAD). The second group consists of progeroid syndromes induced by mutations in genes involved in DNA-repair pathways, such as Werner syndrome (WS), Bloom syndrome (BS), Rothmund-Thomson syndrome (RTS), Cockayne syndrome (CS), xeroderma pigmentosum (XP), trichothiodystrophy (TTD), Fanconi anaemia (FA), Seckel syndrome (SS), ataxia telangiectasia (AT), ataxia telangiectasia-like disorder (ATLD), cerebroretinal microangiopathy with calcifications and cysts (CRMCC), and Nijmegen breakage syndrome (NBN). A subcategory of this group comprises dyskeratosis congenita (DC) and Hoyeraal-Hreidarsson syndrome (HHS), linked to mutations in components of the telomerase complex (see Box 1 for a glossary of terms) that cause telomere attrition.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Clinical features of progeroid syndromes

Box 1. Glossary

Emerin: protein encoded by the EMD gene. Present in the inner nuclear membrane in vertebrates, and highly expressed in cardiac and skeletal muscle. Mutations in emerin cause X-linked recessive Emery-Dreifuss muscular dystrophy, cardiac conduction abnormalities and dilated cardiomyopathy.

Cryptic splice site: splice sites that are usually dormant and can be activated by nearby mutations, often causing genetic diseases.

CST complex: a complex involved in termination of telomere elongation, composed of CTC1, STN1 and TEN1.

Double-strand break (DSB) repair: double-strand breaks (DSBs) can lead to genome rearrangements. Three mechanisms exist to repair DSBs: non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ) and homologous recombination (HR).

Interstrand crosslinks (ICLs): highly toxic DNA lesions that prevent transcription and replication by inhibiting DNA strand separation.

Multipotent cell: progenitor cell that has the gene activation potential to differentiate into multiple, but limited, cell types.

Nucleotide excision repair (NER): DNA-repair mechanism that removes DNA damage induced by ultraviolet (UV) light, mostly thymine dimers and 6,4-photoproducts.

Pluripotent cell: stem cell that has the potential to differentiate into any of the three germ layers: endoderm, mesoderm and ectoderm.

RecQ helicase family: helicases are enzymes important in replication and genome maintenance that unwind paired DNA and translocate in the 3′-to-5′ direction.

Shelterin complex: protein complex that protects mammalian telomeres from DNA-repair mechanisms, in addition to regulating telomerase activity. Subunits of shelterin bind to telomeres and induce the formation of a t-loop, a cap structure that prevents DNA-damage-sensing machinery from mistakenly repairing telomeres. The absence of shelterin causes telomere uncapping and thereby activates damage-signalling pathways that can lead to NHEJ, HR, senescence or apoptosis. Shelterin has six subunits: TRF1, TRF2, POT1, RAP1, TIN2 and TPP1.

Somatotropic axis: consists of growth hormone (GH) and insulin-like growth factors (IGF-I and -II) together with their associated carrier proteins and receptors. Regulates metabolism and other physiological processes. Other hormones, such as insulin, leptin, glucocorticoids and thyroid hormones, modulate GH and IGF synthesis and availability.

Telomerase complex: ribonucleoprotein complex encoded by the TERT, TERC, DKC1 and TEP1 genes that enlarges telomeres by adding the polynucleotide ‘TTAGGG’ to their 3′ end thanks to its reverse transcriptase activity, so that they can protect the ends of the chromosomes from deterioration or from fusion with other chromosomes.

Nuclear architecture instability and premature ageing

The nuclear lamina is a highly regulated membrane barrier that separates the nucleus from the cytoplasm in eukaryotic cells, and contains lamins and other proteins involved in chromatin organization and gene regulation (Burke and Stewart, 2013) (Fig. 1). There are two major types of lamin proteins, the A-type, encoded by the gene LMNA, which includes lamins A and C, and the B-type, encoded by the genes LMNB1 and LMNB2, and includes lamins B1, B2 and B3. Lamin A undergoes complex post-translational processing steps, such as farnesylation, cleavage by the zinc metallopeptidase STE24 (ZMPSTE24), carboxyl methylation by the isoprenylcysteine carboxylmethyltransferase (ICMT), and excision of the farnesylated residue (Fig. 1). Lamin A also interacts with many different proteins, such as the barrier to autointegration factor (BAF), to achieve mitotic and post-mitotic nuclear assembly (Jamin and Wiebe, 2015). Mutations in genes that encode nuclear-lamina proteins cause progeroid syndromes, such as HGPS, NGPS, APSs, RD and MAD (Agarwal et al., 2003; Barthelemy et al., 2015; De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003; Navarro et al., 2005; Puente et al., 2011). In this section, we describe the main clinical features of progeroid syndromes caused by mutations in key elements of the nuclear envelope (Table 1).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Prelamin A physiological and pathological processing and maturation. Processing of prelamin A in (A) normal cells, leading to the generation of mature lamin A and assembly of the normal nuclear envelope, and (B) HGPS cells, where the HGPS-associated mutation (G608G) in the gene encoding prelamin A, LMNA, activates a cryptic splicing site that results in the deletion of 50 amino acids slightly upstream of the C-terminus of prelamin A, encompassing the final cleavage site for ZMPSTE24 and leading to the accumulation of a toxic form of lamin A named progerin. This leads to disruption of the nuclear envelope, detectable as bulging or ‘nuclear blebbing’, which is shown in the representative images of HGPS and NGPS human fibroblasts illustrated below, in comparison to control cells. Lamin A/C (green) and DAPI (blue) staining is shown. Note that nuclear blebbing in NGPS cells is not due to the accumulation of progerin (see main text), and this image has been included purely to demonstrate the phenotype. FTase, farnesyltransferase; ICMT, isoprenylcysteine carboxyl methyltransferase; HGPS, Hutchinson-Gilford progeria syndrome; NGPS, Nestor-Guillermo progeria syndrome; ZMPSTE24, zinc metalloproteinase STE24.

Hutchinson-Gilford progeria syndrome

HGPS is the most prevalent and widely studied accelerated-ageing syndrome. Most cases of HGPS originate from a de novo heterozygous silent mutation in the LMNA gene (G608G). This mutation activates a cryptic splicing site (Box 1) that results in the deletion of 50 amino acids near the C-terminus of prelamin A, which encompasses the final cleavage site for CAAX prenyl protease 1 homolog (ZMPSTE24) to produce lamin A. This leads to the accumulation of a toxic protein called progerin, which disrupts the integrity of the nuclear envelope (Fig. 1) (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). Individuals with HGPS display alopecia (hair loss), atherosclerosis, lipodystrophy, heart infarction and death during puberty (Table 1) (Gordon et al., 2014). Cells derived from these individuals present nuclear shape abnormalities known as ‘blebs’ (Fig. 1B) and shortened telomeres, and undergo premature senescence as a consequence of genome instability (Gonzalo and Kreienkamp, 2015). Progerin also accumulates during physiological ageing, reinforcing the parallels between normal and pathological ageing (Scaffidi and Misteli, 2006). Similar to aged individuals, HGPS individuals demonstrate vascular stiffening, atherosclerotic plaques and calcium dysfunction (Gerhard-Herman et al., 2012; Olive et al., 2010). Nonetheless, some basic features of ageing, such as the deterioration of the nervous system, the immune system deficits and the increased susceptibility to cancer, are not recapitulated in HGPS (Gordon et al., 2014). This is due to the low levels of prelamin A expression in the brain (Jung et al., 2012), and to the presence of a tumour protection mechanism mediated by bromodomain containing protein 4 (BRD4) in cells from individuals with HGPS (Fernandez et al., 2014) (discussed in more detail later).

Atypical progeria syndromes

Several lamin A mutations, including A57P, R133L and L140R, which are predicted to alter key protein-protein interaction domains, are associated with APSs. Individuals with APS show many of the clinical features of HGPS (Table 1), but their cells do not accumulate prelamin A or progerin (Barthelemy et al., 2015).

Restrictive dermopathy and mandibuloacral dysplasia

RD is a rare recessive condition caused by ZMPSTE24 mutations that lead to the accumulation of lamin A precursors (Navarro et al., 2005). MAD is characterized by lipodystrophy and skeletal and metabolic abnormalities (Table 1). MAD with type A lipodystrophy (MADA) is induced by the homozygous R527H LMNA mutation, which leads to accumulation of prelamin A and changes in nuclear architecture (Novelli et al., 2002), whereas MAD with type B lipodystrophy (MADB) is caused by compound heterozygous mutations in ZMPSTE24 (Agarwal et al., 2003).

Néstor-Guillermo progeria syndrome

NGPS is caused by a homozygous mutation (c.34G<A; p.Ala12Thr) in BANF1 (barrier to autointegration Factor 1), which encodes the protein BAF, involved in chromatin organization, nuclear assembly and gene-expression regulation. Fibroblasts from NGPS individuals demonstrate reduced levels of BAF protein, aberrant nuclear morphology, namely blebbing (Fig. 1), and altered subcellular distribution of emerin (see Box 1) (Cabanillas et al., 2011; Puente et al., 2011). The A12T mutation also weakens the binding of BAF to DNA, which is crucial for its many roles in the cell, suggesting that this deficiency contributes to the cellular phenotype observed in NGPS (Paquet et al., 2014). NGPS shares many clinical features with HGPS (Table 1), but, for unknown reasons, lacks cardiovascular defects, which likely contributes to the longer lifespan of NGPS patients (Cabanillas et al., 2011).

Defects in DNA repair, and premature ageing

Damage to nuclear DNA is a direct cause of ageing and cancer, and a decline in DNA repair with age has been described (Vijg and Suh, 2013). Moreover, many progeroid syndromes are caused by defects in DNA repair (Childs et al., 2014; Vermeij et al., 2016). In humans, there are five RecQ helicases – proteins that repair double-strand breaks during DNA replication (Box 1), and maintain genome stability and telomere integrity (Bernstein et al., 2010). Mutations in three of them [WRN (Werner syndrome, RecQ helicase-like), BLM (Bloom syndrome, RecQ helicase-like) and RECQ4 (RecQ helicase-like 4)] are associated with WS, BS and RTS premature-ageing syndromes, respectively. Other DNA-repair proteins altered in progeroid syndromes include the excision-repair cross-complementing (ERCC) family, the FA proteins and the XP proteins, which collaborate to enable DNA nucleotide excision repair (NER) and double-strand-break repair (Fig. 2; Box 1) (Vermeij et al., 2016). Mutations in genes encoding these and other proteins involved in DNA repair are responsible for different premature-ageing disorders, the clinical features of which are summarized below and in Table 1.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Mutations in proteins involved in DNA repair lead to premature ageing syndromes. Diagrams of the proteins involved in (A) double-strand break (DSB) repair, (B) interstrand cross-link (ISL) repair, (C) nucleotide excision repair (NER) and (D) telomere elongation and maintenance, including the shelterin complex, the telomerase complex and the CST (CTC1, STN1 and TEN1) complex (Box 1). Proteins encoded by genes mutated in progeroid syndromes are shown in orange, blue, green and red, whereas non-mutated proteins are shown in grey.

Werner syndrome

WS is caused by mutations in the WRN gene that result in the production of WRN truncated proteins (Yu et al., 1996). Individuals with this disorder display a range of premature-ageing symptoms (Table 1) and a high incidence of cancer that might be related to the chromosomal instability, telomere dysfunction and senescent phenotype exhibited by cells lacking WRN (Crabbe et al., 2007).

Bloom syndrome

BS is caused by mutations in the BLM gene, which encodes the RecQ helicase BLM. These mutations lead to the mislocalization of BLM protein or to the impairment of its helicase or ATPase domains (Machwe et al., 2005). This syndrome is characterized by immunodeficiency and predisposition to cancer, among other features (Table 1) (Ellis et al., 2008).

Rothmund-Thomson syndrome

RTS is caused by mutations in RECQL4, which encodes a helicase localized at telomeres and mitochondria (Croteau et al., 2012). This syndrome is mainly characterized by growth deficiency, skin abnormalities and increased susceptibility to cancer (Table 1) (Puzianowska-Kuznicka and Kuznicki, 2005). The loss of RECQL4 in fibroblasts of affected individuals leads to impaired DNA repair after oxidative stress and to growth arrest, which could explain the dwarfism associated with this disorder (Werner et al., 2006).

Cockayne syndrome, xeroderma pigmentosum and trichothiodystrophy

CS, XP and TTD are a group of related disorders associated with defects in NER (Box 1) (Marteijn et al., 2014). CS is a neurodegenerative disorder caused by mutations in the ERCC6 and ERCC8 genes, and is mainly characterized by neural abnormalities and growth failure (Table 1) (Tan et al., 2005). XP arises from mutation of any of many different genes, including XPA, XPB, XPC, XPG, ERCC4, ERCC6, DDB2 and POLH. This syndrome is characterized by an impaired capacity to repair the damage caused by UV light, which leads to increased cancer susceptibility (Cleaver, 2005). TTD is another rare progeroid disorder generated by mutations in XPB, XPD or TFB5, and is characterized by skin photosensitivity, growth retardation and a reduced life expectancy (Itin et al., 2001).

Fanconi anaemia

Mutations in FA genes, which encode proteins that are involved in DNA repair, such as FANCA or BRCA2, can lead to FA disease. Individuals with FA exhibit a higher cancer susceptibility, bone marrow failure, short stature, skin abnormalities and developmental disabilities (Table 1) (Deakyne and Mazin, 2011). Cells from individuals with FA produce high levels of reactive oxygen species (ROS), which can damage telomeric regions (Uziel et al., 2008). This defect, together with an insufficient DNA-repair system, results in single-strand DNA breaks that induce accelerated telomere shortening. Mutant cells show shorter telomeres and an increase in chromosome-end fusions compared to normal controls, resulting in genomic instability and multinucleated cells (Bogliolo and Surralles, 2015).

Seckel syndrome

SS is caused by mutations in the ATR (ataxia telangiectasia and Rad3-related) gene, which codes for the serine/threonine kinase ATR. SS is characterized by intrauterine growth retardation and postnatal dwarfism (Table 1) (Shanske et al., 1997). ATR protein has a crucial role in preventing replicative stress, sensing DNA damage and consequently arresting the cell cycle, and in maintaining telomere integrity (Pennarun et al., 2010).

Ataxia telangiectasia

AT is caused by mutations in the ATM (ataxia telangiectasia mutated) gene, which encodes a serine/threonine kinase that is activated by DNA double-strand breaks. AT individuals show progressive cerebellar degeneration, pigmentary abnormalities, hair greying and increased cancer susceptibility (Table 1). ATM is involved in DNA-damage signalling, cell cycle arrest and telomere maintenance (Sahin and DePinho, 2010).

Dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome

Telomere shortening is observed during normal ageing both in human and mouse cells, acting as a barrier to tumour growth and contributing to cell senescence (Armanios and Blackburn, 2012). Various premature ageing disorders, such as DC and HHS, are linked to mutations in components of the telomerase complex (Box 1). DC is a rare autosomal-dominant disorder caused by mutations in TERC (telomerase RNA component), TERT (telomerase reverse transcriptase), WRAP53 (WD repeat component, antisense to TP53) or CTC1 (CTS telomere maintenance complex component 1), among other genes (Stanley and Armanios, 2015). X-linked DC is caused by mutations in DKC1 (dyskeratosis congenita 1) (Fig. 2) (Yoon et al., 2006). Individuals with DC present bone marrow failure, cancer predisposition, premature hair greying and osteoporosis (Table 1) (Stanley and Armanios, 2015). HHS is a very rare multisystem disorder that phenocopies DC but with an increased severity (Table 1) (Walne et al., 2013). Mutations responsible for HHS have been identified in RTEL1 (regulator of telomere elongation helicase 1), which encodes a helicase that is essential for telomere maintenance, and ACD (adrenocortical dysplasia homolog), which encodes the shelterin TPP1 (Box 1) (Kocak et al., 2014; Walne et al., 2013).

The development of cellular and mouse models for the study of the progeroid syndromes described above has been extremely useful in order to elucidate the mechanisms underlying such diseases. The most relevant models are described in the following sections.

Cellular models of progeroid syndromes

The generation of patient-derived induced pluripotent stem cells (iPSCs) in recent years has enabled researchers to study specific tissues affected by a disease and to discover new tissue-specific drugs (Studer et al., 2015; Tang et al., 2016). Recently, these approaches have also been used to study different progeroid syndromes and to identify barriers to reprogramming in normally aged and prematurely aged cells.

iPSC generation from progeroid cells

iPSCs from several progeroid syndromes have been successfully generated and differentiated along multiple lineages (Table 2). However, progeria-derived iPSCs normally show reduced reprogramming efficiency in comparison to control cells despite being indistinguishable from normal iPSCs in other ways. In line with this, HGPS and NGPS iPSCs lack disease-specific features, such as nuclear blebs, epigenetic changes or, in the case of HPGS iPSCs, progerin expression, demonstrating the erasure of age-associated marks (Lo Cicero and Nissan, 2015; Soria-Valles et al., 2015a; Xiong et al., 2013). Once differentiated, however, the progeroid iPSC-derived cells show age-associated alterations, frequently mimicking the associated pathologies. These iPSC-derived models have been useful for studying the molecular mechanisms of HGPS and NGPS progerias and for screening drug candidates that could be used to treat these disorders (Pitrez et al., 2016; Soria-Valles et al., 2015b). Likewise, when WS fibroblasts are reprogrammed, their telomeres elongate, indicating that telomere function is restored (Shimamoto et al., 2014). The differentiation of WS iPSCs to mesenchymal stem cells (MSCs) results in a recurrence of premature senescence that is associated with telomere attrition. This phenotype can be rescued by the expression of hTERT or by knocking down p53 (Cheung et al., 2014). Another study, using iPSCs generated from CS fibroblasts, has demonstrated that lack of functional ERCC6 increases cell death and ROS production, and upregulates TP53 relative to normal cells (Andrade et al., 2012).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2.

Progeroid-syndrome-derived iPSCs

XP iPSCs from patients with mutations in XPA have also been developed to produce in vitro models of neurological disorders (Fu et al., 2016). These iPSCs can be differentiated into neural cells, indicating that the expression of wild-type XPA alleles is not required for iPSC generation and differentiation (Ohnishi et al., 2015). Studies with DC-derived iPSCs have shown that, even in the undifferentiated state, these cells can exhibit substantially reduced telomerase levels or mislocalization of telomerase from Cajal bodies to nucleoli, which disables the telomere elongation that normally accompanies reprogramming (Batista et al., 2011). Notably, iPSCs from fibroblasts of individuals with FANCA mutations have an impaired ability to differentiate towards early hemoangiogenic progenitors, which indicates that the hematopoietic phenotype of individuals with FA originates from an early hematopoietic stage (Suzuki et al., 2015). Correction of the FANCA mutation increases reprogramming and differentiation capacities of the resulting cells (Raya et al., 2009).

AT-derived fibroblasts have also been reprogrammed, albeit at a reduced efficiency (Fukawatase et al., 2014). These iPSCs display hypersensitivity to ionizing radiation, alterations in DNA-damage signalling pathways, metabolic changes and cell cycle checkpoint defects. AT-derived iPSCs have been differentiated into functional neurons, providing a unique model for the study of AT-associated neurodegeneration (Nayler et al., 2012).

Surprisingly, iPSCs have not yet been derived from RD, MAD, RTS, TTD, BS or SS cells, nor from APSs. The reason for this might partly rest with the low reprogramming efficiency of progeroid cells owing to a series of reprogramming barriers that are starting to be elucidated, as discussed below.

Barriers to reprogramming in ageing cells

Several features displayed by aged cells, such as genetic damage, telomere shortening and cell senescence, represent barriers that greatly reduce the efficiency of cell reprogramming. The reprogramming process is slow and inefficient in part because the forced expression of the Yamanaka factors is a stressful mechanism that activates apoptosis and cellular senescence via the upregulation of tumour suppressor proteins, including p53, p16 (INK4a) and p21 (CIP1) (Li et al., 2009). Accordingly, the inhibition of these factors improves reprogramming efficiency (Banito and Gil, 2010; Hong et al., 2009). Metabolic studies also indicate that inhibition of mammalian target of rapamycin (mTOR) notably improves the efficiency of iPSC generation (Chen et al., 2011), identifying mTOR as an important repressor of reprogramming.

Interestingly, NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation constitutes another barrier to somatic cell reprogramming in normally and prematurely aged cells (Soria-Valles et al., 2015a). Accordingly, NF-κB inhibition significantly increased the reprogramming efficiency of NGPS and HGPS fibroblasts, and of fibroblasts from advanced-age donors. Progeroid fibroblasts also showed a noticeable overexpression of DOT1L (DOT1-like histone H3-K79 methyltransferase), induced by NF-κB. Consistent with this, DOT1L inhibition increased reprogramming efficiency of progeroid cells and physiologically aged fibroblasts. Remarkably, treatment of progeroid mice with DOT1L inhibitors extends their longevity, implicating DOT1L as a newly identified target for rejuvenation-based approaches (Soria-Valles et al., 2015b).

Cells from individuals with FA failed to be reprogrammed to iPSCs unless the defective FA gene was replaced (Muller et al., 2012; Raya et al., 2009). However, a recent study has revealed that E6 protein from human papillomavirus 16 (HPV16) rescues FA-derived iPSC colony formation via p53 inhibition (Chlon et al., 2014). Consequently, the FA pathway is required for reprogramming through p53-dependent mechanisms, emphasizing the importance of classical tumour suppressors as barriers for cell reprogramming in progeroid syndromes.

Mouse models of progeroid syndromes

Mouse models have been widely used to explore the molecular mechanisms of ageing and progeroid syndromes. Thus, experiments using mice with an extended lifespan or with signs of premature ageing have helped to elucidate the basic processes that affect ageing (Table 3) (Lopez-Otin et al., 2013; Vanhooren and Libert, 2013).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3.

Main mouse models used for the study of progeroid syndromes

In 2002, Pendás et al. and Bergo et al., developed the first HGPS mouse model – Zmpste24-null (Zmpste24−/−) mice – which showed growth retardation, cardiomyopathy, muscular dystrophy, lipodystrophy and premature death (Bergo et al., 2002; Pendas et al., 2002). Studies of these mice demonstrated that the accumulation of farnesylated prelamin A damages the nuclear envelope, hyperactivates p53 signalling, and causes cellular senescence, stem cell dysfunction and a progeroid phenotype (Osorio et al., 2009; Varela et al., 2005). Zmpste24−/− mice are also defective in DNA repair (Liu et al., 2005), and in the p53-dependent upregulation of miR-29, which represses extracellular matrix genes (Ugalde et al., 2011). Extracellular matrix remodelling is a widely known mechanism that promotes renovation of adult tissues, and, consequently, repression of such genes impairs tissue restoration and promotes ageing (Gutierrez-Fernandez et al., 2015). However, this mouse model cannot be used to study the aberrant splicing of LMNA observed in individuals with HGPS, prompting the generation of a mouse strain that carries the HGPS mutation (LMNAG608G) (Osorio et al., 2011). These mice accumulate progerin and phenocopy the main clinical manifestations of human HGPS, such as shortened lifespan and bone and cardiovascular alterations. This model has been widely used to develop new therapeutic strategies for HGPS.

Other mouse models related to the lamin-A–Zmpste24 system have helped to elucidate why individuals with HGPS are not predisposed to cancer despite their elevated levels of DNA damage (Cau et al., 2014; Gordon et al., 2014). Zmpste24 mosaic mice that contain both Zmpste24-proficient cells and Zmpste24−/− cells have revealed a lower incidence of invasive carcinomas compared to mice that are heterozygous for Zmpste24 (de la Rosa et al., 2013). Parallel studies have described another cancer protective mechanism in HGPS cells involving suppression of cell proliferation and metastatic properties owing to an altered pattern of chromatin binding by the transcription regulator BRD4 (Fernandez et al., 2014). Other mouse models with Lmna mutations have been developed, although many of these do not fully recapitulate the progeroid phenotype observed in HGPS or APSs (Das et al., 2013; Poitelon et al., 2012; Varga et al., 2006). Zmpste24−/− mouse models have been used to study the molecular mechanisms of RD and MADB progeroid syndromes, although this mouse model does not fully recapitulate several features of these diseases (Osorio et al., 2009). In summary, many mouse models for laminopathies have been developed and studied in order to elucidate the mechanisms underlying the pathogenesis of these and related progeroid syndromes.

Several mouse models have also been created to mimic the clinical phenotypes associated with WS. Wrn-knockout mice have no obvious signs of accelerated senescence and fail to recapitulate clinical WS features (Lombard et al., 2000). However, Wrn−/−Terc−/− mice exhibit many of the key phenotypes, in support of a role for WRN in telomere maintenance (Chang et al., 2004). Mouse models of BS have also been developed, but their early lethality has hampered their utility for the in vivo study of this disease (Luo et al., 2000). Likewise, mice bearing the most common mutations found in RTS individuals have been generated. These mice show severe growth retardation, hair loss, dry skin and increased cancer susceptibility (Mann et al., 2005). Mutant mice have been developed for all CS-associated genes, most of which develop mild CS-like symptoms (Jaarsma et al., 2013). Mice mutant for Xpa−/− and Xpc−/− have also been reported. Xpc−/− mice demonstrate a reduced lifespan and an increased rate of lung cancer, whereas Xpa−/− mice show no lifespan alterations but exhibit a higher rate of liver carcinomas (Hosseini et al., 2015; Melis et al., 2008). Xpg-deficient mice also display many progeroid features, including loss of subcutaneous fat, osteoporosis, neurodegeneration and a short lifespan (Barnhoorn et al., 2014). Furthermore, DNA damage in mice carrying an Ercc1-Xpf DNA-repair defect triggers a chronic inflammatory response, leading to lipodystrophy (Karakasilioti et al., 2013). Finally, a mouse model of TTD recapitulates the human disorder, demonstrating developmental defects, brittle hair, UV sensitivity, skin abnormalities and reduced lifespan (de Boer et al., 1998).

There are several FA mouse models, all of which are characterized by embryonic or perinatal lethality, gonadal abnormality and associated infertility (Bakker et al., 2013). Nevertheless, most FA mouse models do not show any apparent hematological abnormalities, in contrast with humans with FA, who are affected by life-threatening anaemia. An exception to this is the Fancp mutant mouse, which has lowered numbers of white blood cells and platelets (Langevin et al., 2011). Hematopoietic stem cells (HSCs) from other FA mouse mutants (Fancc, Fancd2 and Fancg) have a reduced repopulating ability and fail to maintain hematopoietic homeostasis under stress conditions (Bakker et al., 2013). Fancd2-, Fancf- or Fancm-deficient mice also exhibit an increased incidence of tumorigenesis (Bakker et al., 2013). The SS mouse model, characterized by ATR deficiency, shows high levels of replicative stress during embryogenesis and exhibits accelerated ageing, which is further aggravated in a Tp53-null background (Murga et al., 2009). AT mouse models recapitulate many of the characteristics observed in humans with AT, such as growth retardation, infertility, immune defects and increased susceptibility to lymphomas, although neurodegeneration is not observed (Barlow et al., 1996). Additionally, Atm-deficient mice show increased cancer susceptibility and a severe osteopenic phenotype, which is partly caused by a stem cell defect due to decreased expression of IGF, an important regulator of proliferation (Hishiya et al., 2005).

Mouse models of telomere dysfunction in progeroid syndromes have also been generated. The first mutant mouse with telomerase deficiency failed to recapitulate the clinical features of DC. However, when POT1b−a component of the shelterin complex that protects mammalian telomeres−is removed in mice (Box 1), these animals show clinical features of DC (Hockemeyer et al., 2008). Mouse models of APS, HHS, NBN, ATLD or CRMCC are yet to be developed.

Hallmarks of progeroid syndromes

Based on the evidence obtained through experimentation with cellular and animal models, we propose a set of hallmarks for defining the main features of progeroid syndromes, and discuss their relatedness and differences with those of normal ageing (Fig. 3). Defining these molecular hallmarks could help in the design and interpretation of future studies of both physiological and premature ageing, and could also provide clinical benefit by guiding the diagnosis of or therapy for progeroid diseases.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

The molecular and cellular hallmarks of progeroid syndromes. These nine proposed hallmarks recapitulate the most remarkable features common to different progeroid syndromes and define the mechanisms underlying the pathogenesis of these diseases.

Increased DNA damage and defective DNA repair

Both physiologically aged and progeroid cells accumulate genomic damage throughout life (Vijg and Suh, 2013). Somatic mutations and other forms of DNA damage progressively compile within cells from both aged humans and model organisms, affecting essential genes and resulting in dysfunctional cells and impaired organismal homeostasis (Lopez-Otin et al., 2013). Many other age-related changes can also affect DNA repair mechanisms, leading to the accumulation of more genomic damage (Gorbunova et al., 2007). HGPS and RD progeroid cells are particularly susceptible to DNA damage induced by ROS or by ionizing radiation, and show a severely impaired capacity to repair DNA damage (Camozzi et al., 2014). Many progeroid syndromes also present repair defects owing to mutations in RecQ helicases (Box 1), or in proteins belonging to the ERCC and XP families (Bernstein et al., 2010; Marteijn et al., 2014).

Telomere dysfunction

Telomere shortening is observed during normal ageing in both human and mouse cells, and has been linked to a decreased lifespan (Blasco et al., 1997). As discussed earlier, progeroid syndromes such as DC and HHS are caused by mutations in different components of the telomerase complex. Other ageing-related diseases, such as WS, FA, SS, AT, ATLD, NBN and CRMCC, are characterized by telomere dysfunction caused by mutations in genes involved in telomere maintenance and DNA repair (Armanios and Blackburn, 2012). HGPS cells also exhibit accelerated telomere shortening during proliferation in culture (Decker et al., 2009). Notably, the ectopic expression of telomerase in these cells increases their proliferation and lifespan by decreasing progerin-induced activation of the p53 and retinoblastoma (Rb) pathways (Kudlow et al., 2008). Additionally, the association of the shelterin TRF2 (telomere repeat-binding factor 2) with telomeric sequences is stabilized by its colocalization with A-type lamins. LMNA mutations lead to the impaired association of these lamins with TRF2, resulting in telomere loss (Wood et al., 2014). Furthermore, the ectopic expression of progerin in normal fibroblasts results in the accumulation of DNA damage at telomeres and in cell senescence (Cao et al., 2011). These studies suggest that telomere dysfunction and associated defective DNA repair contribute to genomic instability and premature senescence of cells in progeroid syndromes.

Changes in epigenetics and chromatin structure

Chromatin remodelling plays a central role in the regulation of gene expression. As such, altered chromatin structure can lead to aberrant gene expression patterns, altering normal cellular functions and contributing to both normal and premature ageing (Chandra et al., 2015). Aged cells also accumulate epigenetic alterations that alter normal gene expression profiles (Beerman and Rossi, 2015). Accordingly, aged cells exhibit increased levels of histone modifications that promote transcription and global histone loss, inducing chromatin relaxation and the misregulation of gene expression. Such epigenetic changes are present also in cells from prematurely ageing individuals and likely contribute to the progression of the associated diseases (Lopez-Otin et al., 2013). In addition, the downregulation of chromatin remodelling factors, such as HP1α (heterochromatin protein 1 alpha), polycomb proteins and the NuRD complex, occurs during normal ageing and leads to global heterochromatin loss (Pollina and Brunet, 2011). In the context of premature-ageing syndromes, the absence of WRN (in WS) or the accumulation of progerin (in HGPS) also causes loss of heterochromatin and telomere attrition (Shumaker et al., 2006; Zhang et al., 2015). Likewise, cells from NGPS individuals exhibit profound changes in chromatin organization (Loi et al., 2016). In cells from individuals with HGPS, the epigenetic mark H3K27me3 is lost on the inactive X chromosome of affected females, as a consequence of downregulation of EZH2 (enhancer of Zeste homolog 2), the methyltransferase responsible for this mark. HGPS cells also exhibit the downregulation of H3K9me3 but increased levels of H4K20me3, which are epigenetic modifications that are associated with global repression of transcription (Shumaker et al., 2006). However, in a different study, increased levels of H3K9me3 were linked to accelerated senescence and compromised genome maintenance (Liu et al., 2013).

Sirtuin 1 (SIRT1) is thought to contribute to telomere maintenance through deacetylation of epigenetic marks such as H4K16ac (Palacios et al., 2010). By contrast, low levels of acetylation at H4K16 have been shown to correlate with a defective DNA-damage response (DDR) and double-strand-break repair to ionizing radiation (Sharma et al., 2010). In line with this, Zmpste24−/− mice show hypoacetylation of histones H2B and H4 (Osorio et al., 2010), likely due to the diminished association of the histone acetyltransferase Mof (male absent on the first) with the nuclear matrix. Rescue experiments performed either by Mof overexpression or by histone deacetylase inhibition promoted repair protein recruitment to DNA damage sites and substantially ameliorated aging-associated phenotypes in these mice (Krishnan et al., 2011).

Heterochromatin alterations have also been observed in other syndromes, such as an active heterochromatinization process mediated by SIRT1 in XP or CS cells after UV irradiation (Velez-Cruz et al., 2013), and the presence of unstable heterochromatin in FA cells (Edelman and Lin, 2001). Although epigenetic changes have not yet been identified in all progeroid syndromes, the frequent occurrence of both epigenetic and chromatin alterations tempt us to speculate that such defects are general features of these diseases.

Aberrant nuclear architecture

Several progeroid syndromes−including HGPS, NGPS, APSs, RD and MAD−are associated with significant perturbations in nuclear organization and loss of nuclear envelope stability. In the case of HGPS, the presence of the farnesyl group in progerin, owing to the aberrant processing of lamin A, leads to progerin association with the inner nuclear membrane, generating defects in nuclear shape (Fig. 1) (Goldman et al., 2004). Such features are also observed in healthy ageing individuals owing to the sporadic activation of the same cryptic splice site in LMNA as in HGPS, whereas inhibition of this splice site reverses the nuclear defects associated with ageing (Righolt et al., 2011; Scaffidi and Misteli, 2006). Several studies have suggested that alterations in the nuclear lamina might lead to premature ageing by affecting the transcription profile of adult epithelial and mesenchymal stem cells and thereby interfering with their ability to retain an undifferentiated state (Espada et al., 2008; Scaffidi and Misteli, 2008). Progeroid fibroblasts obtained from NGPS individuals also show profound abnormalities in the nuclear lamina (Fig. 1) that can be rescued by the ectopic expression of wild-type BANF1 (Puente et al., 2011; Soria-Valles et al., 2015a). Furthermore, cells from individuals with RD show an abnormal nuclear shape and heterogeneous deposits of unprocessed prelamin A (Columbaro et al., 2010). Severe nuclear morphological abnormalities are also observed in MAD and APS cells (Barthelemy et al., 2015). Collectively, these findings highlight the relevance of nuclear lamina aberrations as important features of different progeroid syndromes.

Defects in cell cycle and mitosis

Cell cycle regulation is critically important for repairing genetic damage and preventing uncontrolled cell division. Changes in cell cycle dynamics, such as upregulation of p16 and other cell cycle inhibitors, are observed during physiological ageing and cellular senescence, and consequently represent valuable markers for the ageing process (Coppe et al., 2011). Nuclear envelope changes during cell division play a major role in the control of cell cycle progression (Camozzi et al., 2014). Accordingly, the targeting of nuclear lamina components into daughter cell nuclei in early G1 and cytokinesis progression is impaired in HGPS cells owing to the abnormal processing of lamin A (Dechat et al., 2007). FA proteins are essential for arresting the cell cycle until DNA damage is restored; thus, cells from FA patients have defects in DNA repair (Bogliolo and Surralles, 2015). Individuals with SS display an impaired G2/M checkpoint arrest and an increased number of centrosomes in mitotic cells (Griffith et al., 2008). Moreover, insufficiency of BubR1, a key mitotic checkpoint protein, causes aneuploidy, short lifespan, cachectic dwarfism, cataracts and other progeroid features (Baker et al., 2004).

Cellular senescence

Cellular senescence is a state of stable cell cycle arrest and loss of replicative capacity that mainly results from DNA damage, oxidative stress and telomere shortening (van Deursen, 2014). In HGPS cells, progerin-induced senescence has been partially linked to p53 activation, a feature that is recapitulated in mouse models of this progeroid syndrome (Varela et al., 2005). Cells from NGPS patients also show premature cellular senescence characterized by markers such as senescence-associated β-galactosidase (SA-β-gal) staining, senescence-associated heterochromatin foci, increased levels of p16 and significant loss of lamin B1 (Soria-Valles et al., 2015a). Individuals affected by APS also present senescence phenotypes, driven by a dramatic reduction in lamin B1 expression (Bercht Pfleghaar et al., 2015). Likewise, fibroblasts from WS and SS patients show premature cellular senescence induced by replicative stress and faulty DNA repair, primarily due to the activation of stress kinase p38 (Davis et al., 2007; Tivey et al., 2013). Increased SA-β-gal staining and higher expression of p16 and p21 are also observed in BLM-, WRN- and RECQL4-depleted human fibroblasts (Lu et al., 2014). Furthermore, cells from Xpc−/− mice show increased β-galactosidase activity and high levels of progerin, p16 and ROS (Hosseini et al., 2015). Moreover, a mouse model of SS, characterized by a severe deficiency in ATR, shows accelerated ageing that is further aggravated by the loss of p53 (Murga et al., 2009). Hematopoietic stem cell senescence has also been reported in DC and FA (Stockklausner et al., 2015; Zhang et al., 2007).

Metabolic defects

The ageing process is accompanied by many metabolic alterations, such as insulin resistance and physiological decline in growth hormone (GH), insulin-like growth factor-1 (IGF-1) and sex steroids. Accordingly, the insulin and IGF-1 signalling (IIS) pathway is extensively involved in ageing (Lopez-Otin et al., 2013). Moreover, dietary restriction (DR) increases healthspan in many organisms, further supporting a role for metabolism in ageing (Barzilai et al., 2012). Progeroid syndromes are also accompanied by metabolic changes. Zmpste24−/− mice exhibit profound transcriptional alterations in circulating levels of GH and IGF-1 (Marino et al., 2010), as well as changes in metabolic pathways that are associated with autophagy induction (Marino et al., 2008). Metabolic alterations are also present in progeroid syndromes that feature defects in DNA repair. Wrn-deficient mice exhibit hypertriglyceridemia and insulin resistance (Lebel and Leder, 1998). ERCC1-null mice show a shift toward anabolism and decreased GH-IGF-1 signalling (Niedernhofer et al., 2006), whereas CS mouse models show systemic suppression of the GH-IGF-I somatotropic axis (Box 1), increased antioxidant responses and hypoglycaemia (van der Pluijm et al., 2007). These studies suggest that unrepaired DNA damage induces a highly conserved metabolic response that is mediated by the IIS pathway, which redistributes resources from growth and proliferation for the preservation and protection of somatic integrity (Liao and Kennedy, 2014; Schumacher et al., 2009). Furthermore, mice with telomere dysfunction exhibit a marked deficiency in IGF-I-mTOR signalling, impaired energy homeostasis and suppressed mitochondrial biogenesis (Missios et al., 2014). Notably, mitochondrial dysfunction has been linked to the pathogenesis of progeroid syndromes such as HGPS and CS (Rivera-Torres et al., 2013; Scheibye-Knudsen et al., 2013). Cells derived from HGPS patients show a marked downregulation of mitochondrial oxidative phosphorylation proteins, accompanied by mitochondrial dysfunction (Rivera-Torres et al., 2013). These metabolic and mitochondrial alterations have inspired the development of different strategies for the treatment of progeroid syndromes (discussed below).

Inflammation

Chronic inflammation is associated with normal and pathological ageing (Lopez-Otin et al., 2013). In line with this, a pro-inflammatory phenotype, named ‘inflammageing’, has been observed in mammals during ageing (Salminen et al., 2012). Moreover, senescent cells exhibit a senescence-associated secretory phenotype (SASP) characterized by the secretion of increasing levels of factors that alter their microenvironment in a paracrine manner, reinforcing senescence and activating immune surveillance. This phenomenon is mainly regulated by NF-κB (Acosta et al., 2013; Chien et al., 2011). We have recently found that the aberrant activation of NF-κB by ATM in mouse models of progeroid laminopathies induces the overexpression of pro-inflammatory cytokines and contributes to the pathogenesis of these syndromes (Osorio et al., 2012). Likewise, knocking down Nfkb1 in mice causes premature ageing. Accordingly, the accumulation of senescent cells in Nfkb1−/− tissues is blocked by the administration of anti-inflammatory drugs to these mice (Jurk et al., 2014). A recent study has also demonstrated that age-associated NF-κB hyperactivation impairs the generation of iPSCs by evoking the reprogramming repressor DOT1L, which promotes senescence signals and downregulates pluripotency genes (Soria-Valles et al., 2015a). An inflammatory phenotype associated with premature ageing has also been linked to WS (Goto et al., 2012). Similarly, mouse models of FA show inflammation-mediated upregulation of Notch signalling, which correlates with a decreased self-renewal capacity of FA HSCs (Du et al., 2013).

Stem cell exhaustion

The ageing process is accompanied by a decrease in tissue regeneration and homeostasis, due to a decline in stem cell functions as a consequence of DNA damage, changes in tissue environment and alterations in tumour suppressor gene expression (Behrens et al., 2014). Because stem cells regenerate many adult tissues, changes in these cells likely contribute to the development of age-related diseases and to accelerated ageing syndromes. Consistent with this, progerin accumulation reduces the proliferative and differentiation capacity of pluripotent and multipotent (Box 1) mouse and human cells (Pacheco et al., 2014; Rosengardten et al., 2011). Furthermore, muscle-derived stem/progenitor cells (MDSPCs) from old and progeroid mice have proliferation and differentiation defects, whereas intraperitoneal administration of MDSPCs from young wild-type mice to progeroid mice confers a significant extension of lifespan and health via the secretion of certain factors that act systemically (Lavasani et al., 2012). Hematopoietic stem cell senescence has been described in the context of many progeroid syndromes. For example, TERT mutations that cause DC lead to cellular senescence and to the loss of CD34+ hematopoietic stem cells (Stockklausner et al., 2015). Moreover, TNFα induces premature senescence in bone marrow HSCs and in other tissues of FA mouse models. This induction correlates with ROS accumulation and oxidative DNA damage (Zhang et al., 2007). Together, these studies demonstrate the close relationship between progeroid syndromes and stem cell exhaustion, highlighting the importance of using cellular models to further understand the underlying pathobiology of these diseases and to guide the development of appropriate therapies.

Therapeutic and rejuvenation strategies

Our improved understanding of the molecular basis of the progeroid syndromes has guided the development of therapeutic strategies for these disorders, particularly for HGPS (Gordon et al., 2014). Because progerin is permanently farnesylated, the first therapeutic strategy for treating HGPS involved the use of farnesyltransferase inhibitors (FTIs), such as lonafarnib, which has been used as a potential anticancer drug and had tolerable side effects in children. However, lonafarnib led to only limited improvements of symptoms in HGPS patients (Gordon et al., 2012), in part because, following FTI treatment, progerin is geranylgeranylated and gives rise to another toxic form of prelamin A (Varela et al., 2008). Consequently, an efficient blockade of progerin farnesylation must prevent both farnesylation and geranylgeranylation modifications, which provides the rationale behind a combined therapeutic approach that uses statins and aminobisphosphonates (Varela et al., 2008). This strategy has been successfully tested in Zmpste24−/− mice and is currently being evaluated for the treatment of individuals with HGPS (clinical trials: NCT00425607, NCT00879034 and NCT00916747).

Since these first strategies for HGPS treatment were described, additional therapies have been tested, with promising results, in mouse and cellular models of premature ageing. Many of these interventions derive from recent anti-ageing approaches designed to address alterations in cellular processes, such as nutrient-sensing, mitochondrial efficiency and autophagy, which are, as highlighted above, also deficient in progeria (de Cabo et al., 2014; Lopez-Otin et al., 2013). One such approach is treatment with the mTOR inhibitor rapamycin, which can suppress nuclear structure defects and postpone senescence in HGPS fibroblasts in vitro by inducing progerin clearance through autophagy (Cao et al., 2011). Additionally, the SIRT1 activator resveratrol rescues adult stem cell decline, slows down body weight loss and extends lifespan in Zmpste24−/− progeroid mice (Liu et al., 2012). Likewise, the administration of IGF-I to these mice has proven to positively affect both their health and lifespan (Marino et al., 2010).

Beyond these metabolic interventions, and because HGPS is caused by the activation of an alternative splice site, RNA therapy is another option for the treatment of progeria. Morpholino antisense oligonucleotides targeted to the altered splice site were first applied in HGPS fibroblasts to reduce progerin synthesis (Scaffidi and Misteli, 2005). This approach was also successfully used in the LmnaG609G HGPS mouse model, in which it led to a significant lifespan extension (Osorio et al., 2011). More recently, DOT1L inhibitors have proven to be effective as a rejuvenation strategy for both physiologically aged and HGPS and NGPS progeroid human cells (Soria-Valles et al., 2015a), and the treatment of Zmpste24−/− mice with DOT1L inhibitors increases their longevity and ameliorates their progeroid phenotypes (Soria-Valles et al., 2015a). Moreover, treatment of HGPS cells with a small molecule called ‘remodelin’, which targets the acetyltransferase NAT10, improves nuclear architecture and overall fitness of these progeroid cells (Larrieu et al., 2014). Other potentially beneficial HGPS treatments studied in cell-based and animal models include the administration of sodium salicylate, which inhibits the IκB kinase (IKK) complex (Osorio et al., 2012), pyrophosphate (Villa-Bellosta et al., 2013), methylene blue (Xiong et al., 2016) and Icmt inhibitors (Ibrahim et al., 2013).

Treatment with rapamycin has also been proposed as a therapeutic strategy for MAD because it efficiently triggers lysosomal degradation of farnesylated prelamin A (Camozzi et al., 2014). Resveratrol has proven to be efficient in reversing some of the clinically relevant phenotypes in Wrn-deficient mice, such as insulin resistance and liver steatosis, although it did not improve hypertriglyceridemia or inflammatory stress, nor extend the lifespan of these mice. Resveratrol-treated mutant mice also exhibited an increase in the frequency of different tumours (Labbe et al., 2011), and failed to show improvements in HGPS-associated bone defects (Strandgren et al., 2015). A high-fat diet rescues the metabolic, transcriptomic and behavioural phenotypes of a CS mouse model, whereas β-hydroxybutyrate, PARP (poly ADP ribose polymerase) inhibition and NAD+ supplementation can also rescue CS-associated phenotypes through activation of SIRT1, which is involved in cell cycle regulation and response to stressors (Scheibye-Knudsen et al., 2014). The reversal of mitochondrial defects in CS-derived cells using serine protease inhibitors has also been described (Chatre et al., 2015). Similarly, a glucose-enriched diet ameliorates the impaired energy homeostasis phenotype observed in mice with telomere dysfunctions, through the activation of glycolysis, mitochondrial biogenesis and oxidative glucose metabolism (Missios et al., 2014).

Recently, the clearance of senescent cells has been proposed as a promising strategy to promote healthy ageing, mainly through the administration of so-called ‘senolytic’ pharmacological agents that induce the death of senescent cells (Roos et al., 2016). Clearance of such cells in BubR1 hypomorphic progeroid mice delayed the onset of their ageing phenotype and attenuated its progression (Childs et al., 2015). Selective clearance of senescent cells was also shown to be an effective strategy for rejuvenation of tissue stem cells in normally ageing mice (Chang et al., 2016).

Read-through of premature termination codons in cells from WS and XP patients has been achieved using aminoglycosides: this restores WRN functionality in WS cells (Agrelo et al., 2015) and increases XPC protein production in XP cells (Kuschal et al., 2015). Genetic approaches have also been used to correct XP human cells (Dupuy and Sarasin, 2015), whereas genetic depletion of one allele of the p65 subunit of NF-κB or treatment with IKK inhibitors delays the age-related symptoms and pathologies of XFEPS (XPF-ERCC1 progeroid syndrome) mice, which harbour mutations in ERCC1 (involved in DNA excision repair) (Tilstra et al., 2012).

Another therapeutic option is the synthetic steroid danazol, which has anti-gonadotropic and anti-estrogenic activities and is capable of slowing down the progression of pulmonary fibrosis in individuals with DC (Zlateska et al., 2015). In the case of FA, treatment with p38 MAP-kinase inhibitors has improved the repopulating ability of Fancc-deficient HSCs (Saadatzadeh et al., 2009). Resveratrol also partially rescues the reduced repopulating ability of Fancd2-deficient HSCs (Zhang et al., 2010). Treating SS fibroblasts with p38 inhibitors can also restore their reduced replicative capacity in vitro and ameliorate their aged morphology (Tivey et al., 2013).

Importantly, recent studies suggest that the rate of ageing cannot only be modified by environmental and genetic factors, but also reversed (Freije and Lopez-Otin, 2012; Rando and Chang, 2012). Many rejuvenation strategies are based on epigenetic reprogramming, such as depletion of the methyltransferase Suv39h1, which reduces H3K9me3 levels, improves DNA repair capacity and delays senescence in progeroid cells, and also extends lifespan in progeroid mice (Ibrahim et al., 2013; Liu et al., 2013). In the future, strategies developed to treat progeroid syndromes could also be considered as treatments for pathologies associated with physiological ageing, as long as they share the same mechanisms. This would certainly expand the benefits of these discoveries to a wider medical community. Although many treatment options for individuals with ageing pathologies have been successfully tested in cellular and animal models, initiating therapeutic trials for rare diseases such as progeroid syndromes is an exceptionally difficult task because of the absence of longitudinal studies on different cohorts of patients. Also, the occurrence of only a low number of cases in any given country requires the setting up of clinical trials that follow identical protocols in different parts of the world (Osorio et al., 2011).

Conclusions

Over recent years, advancements in our understanding of the genetic and molecular bases of premature aging disorders through the use of cellular and mouse models have led to a better understanding of the onset and progression of their clinical manifestations. On the basis of these studies, we have herein classified progeroid syndromes in two main categories, depending on the key molecular mechanisms involved. This classification scheme could provide a framework for the better understanding of the aetiology, biology and pathogenesis of progeroid syndromes. We have also appraised the latest findings made through the use of in vitro and in vivo models, which have helped to elucidate the processes that contribute to pathological and physiological ageing, and to characterize the cellular and organismal phenotypes of progeroid syndromes. Consequently, we have proposed nine hallmarks that characterize most progeroid syndromes, which extensively correlate with the nine hallmarks of ageing recently proposed (Lopez-Otin et al., 2013). Such hallmarks compile the most notable characteristics of progeroid syndromes and define the mechanisms underlying their pathogenesis, which might contribute to laying the groundwork for future studies on physiological and pathological ageing.

Finally, we have highlighted emerging therapies that could help to ameliorate the accelerated ageing phenotypes that underpin progeroid syndromes. It is well known that setting up of therapeutic trials for rare diseases is a difficult task owing to the lack of clinical correlational studies with similar evaluation guidelines and sufficient cohorts of patients (Osorio et al., 2011). This can present an obstacle to the testing of therapeutic approaches developed based on findings in cell- and animal-based studies. Nonetheless, a deeper characterization of the genetics and mechanisms underlying progeroid syndromes might enable earlier diagnosis and a better understanding of how the disease will progress in specific individuals, providing opportunities for earlier intervention and personalized treatment. Moreover, research focused on delaying or ameliorating physiological ageing could also contribute to developing a suitable therapeutic approach for progeroid syndromes.

Acknowledgements

We acknowledge M. Carrero and all the members of López-Otín's lab for their support and constructive discussions during the preparation of this manuscript. We apologize for omission of relevant works due to space constraints.

Footnotes

  • Competing interests

    C.L.-O. is an Investigator of the Botin Foundation supported by Banco Santander through its Santander Universities Global Division.

  • Author contributions

    D.C., C.S.-V. and C.L.-O. contributed to the design and writing of the review, and D.C. created the figures.

  • Funding

    The work was supported by grants from Ministerio de Economía y Competitividad - Spain [grant number SAF2014-52413-R]; Gobierno del Principado de Asturias; Instituto de Salud Carlos III (RTICC) [grant number RD12/0036/0067] Spain; and Energias de Portugal (EDP) Foundation. We also thank the generous support by J. I. Cabrera. The Instituto Universitario de Oncología is supported by Fundación Bancaria Caja de Ahorros de Asturias.

  • © 2016. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

References

  1. ↵
    1. Acosta, J. C.,
    2. Banito, A.,
    3. Wuestefeld, T.,
    4. Georgilis, A.,
    5. Janich, P.,
    6. Morton, J. P.,
    7. Athineos, D.,
    8. Kang, T.-W.,
    9. Lasitschka, F.,
    10. Andrulis, M. et al.
    (2013). A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978-990. doi:10.1038/ncb2784
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Agarwal, A. K.,
    2. Fryns, J.-P.,
    3. Auchus, R. J. and
    4. Garg, A.
    (2003). Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum. Mol. Genet. 12, 1995-2001. doi:10.1093/hmg/ddg213
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Agrelo, R.,
    2. Sutz, M. A.,
    3. Setien, F.,
    4. Aldunate, F.,
    5. Esteller, M.,
    6. Da Costa, V. and
    7. Achenbach, R.
    (2015). A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies. Epigenetics 10, 329-341. doi:10.1080/15592294.2015.1027853
    OpenUrlCrossRefPubMed
  4. ↵
    1. Andrade, L. N. d. S.,
    2. Nathanson, J. L.,
    3. Yeo, G. W.,
    4. Menck, C. F. M. and
    5. Muotri, A. R.
    (2012). Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome. Hum. Mol. Genet. 21, 3825-3834. doi:10.1093/hmg/dds211
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Armanios, M. and
    2. Blackburn, E. H.
    (2012). The telomere syndromes. Nat. Rev. Genet. 13, 693-704. doi:10.1038/nrg3246
    OpenUrlCrossRefPubMed
  6. ↵
    1. Baker, D. J.,
    2. Jeganathan, K. B.,
    3. Cameron, J. D.,
    4. Thompson, M.,
    5. Juneja, S.,
    6. Kopecka, A.,
    7. Kumar, R.,
    8. Jenkins, R. B.,
    9. de Groen, P. C.,
    10. Roche, P. et al.
    (2004). BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat. Genet. 36, 744-749. doi:10.1038/ng1382
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Bakker, S. T.,
    2. de Winter, J. P. and
    3. te Riele, H.
    (2013). Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models. Dis. Model. Mech. 6, 40-47. doi:10.1242/dmm.009795
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Banito, A. and
    2. Gil, J.
    (2010). Induced pluripotent stem cells and senescence: learning the biology to improve the technology. EMBO Rep. 11, 353-359. doi:10.1038/embor.2010.47
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Barlow, C.,
    2. Hirotsune, S.,
    3. Paylor, R.,
    4. Liyanage, M.,
    5. Eckhaus, M.,
    6. Collins, F.,
    7. Shiloh, Y.,
    8. Crawley, J. N.,
    9. Ried, T.,
    10. Tagle, D. et al.
    (1996). Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159-171. doi:10.1016/S0092-8674(00)80086-0
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Barnhoorn, S.,
    2. Uittenboogaard, L. M.,
    3. Jaarsma, D.,
    4. Vermeij, W. P.,
    5. Tresini, M.,
    6. Weymaere, M.,
    7. Menoni, H.,
    8. Brandt, R. M. C.,
    9. de Waard, M. C.,
    10. Botter, S. M. et al.
    (2014). Cell-autonomous progeroid changes in conditional mouse models for repair endonuclease XPG deficiency. PLoS Genet. 10, e1004686. doi:10.1371/journal.pgen.1004686
    OpenUrlCrossRefPubMed
  11. ↵
    1. Barthelemy, F.,
    2. Navarro, C.,
    3. Fayek, R.,
    4. Da Silva, N.,
    5. Roll, P.,
    6. Sigaudy, S.,
    7. Oshima, J.,
    8. Bonne, G.,
    9. Papadopoulou-Legbelou, K.,
    10. Evangeliou, A. E. et al.
    (2015). Truncated prelamin A expression in HGPS-like patients: a transcriptional study. Eur. J. Hum. Genet. 23, 1051-1061. doi:10.1038/ejhg.2014.239
    OpenUrlCrossRefPubMed
  12. ↵
    1. Barzilai, N.,
    2. Huffman, D. M.,
    3. Muzumdar, R. H. and
    4. Bartke, A.
    (2012). The critical role of metabolic pathways in aging. Diabetes 61, 1315-1322. doi:10.2337/db11-1300
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Batista, L. F. Z.,
    2. Pech, M. F.,
    3. Zhong, F. L.,
    4. Nguyen, H. N.,
    5. Xie, K. T.,
    6. Zaug, A. J.,
    7. Crary, S. M.,
    8. Choi, J.,
    9. Sebastiano, V.,
    10. Cherry, A. et al.
    (2011). Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474, 399-402. doi:10.1038/nature10084
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Beerman, I. and
    2. Rossi, D. J.
    (2015). Epigenetic control of stem cell potential during homeostasis, aging, and disease. Cell Stem Cell 16, 613-625. doi:10.1016/j.stem.2015.05.009
    OpenUrlCrossRefPubMed
  15. ↵
    1. Behrens, A.,
    2. van Deursen, J. M.,
    3. Rudolph, K. L. and
    4. Schumacher, B.
    (2014). Impact of genomic damage and ageing on stem cell function. Nat. Cell Biol. 16, 201-207. doi:10.1038/ncb2928
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Bercht Pfleghaar, K.,
    2. Taimen, P.,
    3. Butin-Israeli, V.,
    4. Shimi, T.,
    5. Langer-Freitag, S.,
    6. Markaki, Y.,
    7. Goldman, A. E.,
    8. Wehnert, M. and
    9. Goldman, R. D.
    (2015). Gene-rich chromosomal regions are preferentially localized in the lamin B deficient nuclear blebs of atypical progeria cells. Nucleus 6, 66-76. doi:10.1080/19491034.2015.1004256
    OpenUrlCrossRefPubMed
  17. ↵
    1. Bergo, M. O.,
    2. Gavino, B.,
    3. Ross, J.,
    4. Schmidt, W. K.,
    5. Hong, C.,
    6. Kendall, L. V.,
    7. Mohr, A.,
    8. Meta, M.,
    9. Genant, H.,
    10. Jiang, Y. et al.
    (2002). Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. USA 99, 13049-13054. doi:10.1073/pnas.192460799
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Bernstein, K. A.,
    2. Gangloff, S. and
    3. Rothstein, R.
    (2010). The RecQ DNA helicases in DNA repair. Annu. Rev. Genet. 44, 393-417. doi:10.1146/annurev-genet-102209-163602
    OpenUrlCrossRefPubMedWeb of Science
    1. Bisserbe, A.,
    2. Tertian, G.,
    3. Buffet, C.,
    4. Turhan, A.,
    5. Lambotte, O.,
    6. Nasser, G.,
    7. Alvin, P.,
    8. Tardieu, M.,
    9. Riant, F.,
    10. Bergametti, F. et al.
    (2015). Cerebro-retinal microangiopathy with calcifications and cysts due to recessive mutations in the CTC1 gene. Rev. Neurol. 171, 445-449. doi:10.1016/j.neurol.2015.01.566
    OpenUrlCrossRefPubMed
  19. ↵
    1. Blasco, M. A.,
    2. Lee, H.-W.,
    3. Hande, M. P.,
    4. Samper, E.,
    5. Lansdorp, P. M.,
    6. DePinho, R. A. and
    7. Greider, C. W.
    (1997). Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25-34. doi:10.1016/S0092-8674(01)80006-4
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Bogliolo, M. and
    2. Surralles, J.
    (2015). Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics. Curr. Opin. Genet. Dev. 33, 32-40. doi:10.1016/j.gde.2015.07.002
    OpenUrlCrossRefPubMed
  21. ↵
    1. Burke, B. and
    2. Stewart, C. L.
    (2013). The nuclear lamins: flexibility in function. Nat. Rev. Mol. Cell Biol. 14, 13-24. doi:10.1038/nrm3488
    OpenUrlCrossRefPubMed
  22. ↵
    1. Cabanillas, R.,
    2. Cadiñanos, J.,
    3. Villameytide, J. A. F.,
    4. Pérez, M.,
    5. Longo, J.,
    6. Richard, J. M.,
    7. Álvarez, R.,
    8. Durán, N. S.,
    9. Illán, R.,
    10. González, D. J. et al.
    (2011). Néstor-Guillermo progeria syndrome: a novel premature aging condition with early onset and chronic development caused by BANF1 mutations. Am. J. Med. Genet. A 155, 2617-2625. doi:10.1002/ajmg.a.34249
    OpenUrlCrossRef
  23. ↵
    1. Camozzi, D.,
    2. Capanni, C.,
    3. Cenni, V.,
    4. Mattioli, E.,
    5. Columbaro, M.,
    6. Squarzoni, S. and
    7. Lattanzi, G.
    (2014). Diverse lamin-dependent mechanisms interact to control chromatin dynamics. Focus on laminopathies. Nucleus 5, 427-440. doi:10.4161/nucl.36289
    OpenUrlCrossRefPubMed
  24. ↵
    1. Cao, K.,
    2. Blair, C. D.,
    3. Faddah, D. A.,
    4. Kieckhaefer, J. E.,
    5. Olive, M.,
    6. Erdos, M. R.,
    7. Nabel, E. G. and
    8. Collins, F. S.
    (2011). Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J. Clin. Invest. 121, 2833-2844. doi:10.1172/JCI43578
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Cau, P.,
    2. Navarro, C.,
    3. Harhouri, K.,
    4. Roll, P.,
    5. Sigaudy, S.,
    6. Kaspi, E.,
    7. Perrin, S.,
    8. De Sandre-Giovannoli, A. and
    9. Lévy, N.
    (2014). Nuclear matrix, nuclear envelope and premature aging syndromes in a translational research perspective. Semin. Cell Dev. Biol. 29, 125-147. doi:10.1016/j.semcdb.2014.03.021
    OpenUrlCrossRefPubMed
  26. ↵
    1. Chandra, T.,
    2. Ewels, P. A.,
    3. Schoenfelder, S.,
    4. Furlan-Magaril, M.,
    5. Wingett, S. W.,
    6. Kirschner, K.,
    7. Thuret, J.-Y.,
    8. Andrews, S.,
    9. Fraser, P. and
    10. Reik, W.
    (2015). Global reorganization of the nuclear landscape in senescent cells. Cell Rep. 10, 471-483. doi:10.1016/j.celrep.2014.12.055
    OpenUrlCrossRefPubMed
  27. ↵
    1. Chang, S.,
    2. Multani, A. S.,
    3. Cabrera, N. G.,
    4. Naylor, M. L.,
    5. Laud, P.,
    6. Lombard, D.,
    7. Pathak, S.,
    8. Guarente, L. and
    9. DePinho, R. A.
    (2004). Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat. Genet. 36, 877-882. doi:10.1038/ng1389
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Chang, J.,
    2. Wang, Y.,
    3. Shao, L.,
    4. Laberge, R.-M.,
    5. Demaria, M.,
    6. Campisi, J.,
    7. Janakiraman, K.,
    8. Sharpless, N. E.,
    9. Ding, S.,
    10. Feng, W. et al.
    (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78-83. doi:10.1038/nm.4010
    OpenUrlCrossRefPubMed
  29. ↵
    1. Chatre, L.,
    2. Biard, D. S. F.,
    3. Sarasin, A. and
    4. Ricchetti, M.
    (2015). Reversal of mitochondrial defects with CSB-dependent serine protease inhibitors in patient cells of the progeroid Cockayne syndrome. Proc. Natl. Acad. Sci. USA 112, E2910-E2919. doi:10.1073/pnas.1422264112
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Chen, T.,
    2. Shen, L.,
    3. Yu, J.,
    4. Wan, H.,
    5. Guo, A.,
    6. Chen, J.,
    7. Long, Y.,
    8. Zhao, J. and
    9. Pei, G.
    (2011). Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 10, 908-911. doi:10.1111/j.1474-9726.2011.00722.x
    OpenUrlCrossRefPubMed
  31. ↵
    1. Cheung, H.-H.,
    2. Liu, X.,
    3. Canterel-Thouennon, L.,
    4. Li, L.,
    5. Edmonson, C. and
    6. Rennert, O. M.
    (2014). Telomerase protects werner syndrome lineage-specific stem cells from premature aging. Stem Cell Rep. 2, 534-546. doi:10.1016/j.stemcr.2014.02.006
    OpenUrlCrossRef
  32. ↵
    1. Chien, Y.,
    2. Scuoppo, C.,
    3. Wang, X.,
    4. Fang, X.,
    5. Balgley, B.,
    6. Bolden, J. E.,
    7. Premsrirut, P.,
    8. Luo, W.,
    9. Chicas, A.,
    10. Lee, C. S. et al.
    (2011). Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125-2136. doi:10.1101/gad.17276711
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Childs, B. G.,
    2. Baker, D. J.,
    3. Kirkland, J. L.,
    4. Campisi, J. and
    5. van Deursen, J. M.
    (2014). Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 15, 1139-1153. doi:10.15252/embr.201439245
    OpenUrlCrossRefPubMed
  34. ↵
    1. Childs, B. G.,
    2. Durik, M.,
    3. Baker, D. J. and
    4. van Deursen, J. M.
    (2015). Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21, 1424-1435. doi:10.1038/nm.4000
    OpenUrlCrossRefPubMed
  35. ↵
    1. Chlon, T. M.,
    2. Hoskins, E. E.,
    3. Mayhew, C. N.,
    4. Wikenheiser-Brokamp, K. A.,
    5. Davies, S. M.,
    6. Mehta, P.,
    7. Myers, K. C.,
    8. Wells, J. M. and
    9. Wells, S. I.
    (2014). High-risk human papillomavirus E6 protein promotes reprogramming of Fanconi anemia patient cells through repression of p53 but does not allow for sustained growth of induced pluripotent stem cells. J. Virol. 88, 11315-11326. doi:10.1128/JVI.01533-14
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Cleaver, J. E.
    (2005). Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat. Rev. Cancer 5, 564-573. doi:10.1038/nrc1652
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Columbaro, M.,
    2. Mattioli, E.,
    3. Schena, E.,
    4. Capanni, C.,
    5. Cenni, V.,
    6. Levy, N.,
    7. Navarro, C. L.,
    8. Del Coco, R.,
    9. Squarzoni, S.,
    10. Camozzi, D. et al.
    (2010). Prelamin A processing and functional effects in restrictive dermopathy. Cell Cycle 9, 4766-4768. doi:10.4161/cc.9.23.14210
    OpenUrlCrossRefPubMed
  38. ↵
    1. Coppe, J.-P.,
    2. Rodier, F.,
    3. Patil, C. K.,
    4. Freund, A.,
    5. Desprez, P.-Y. and
    6. Campisi, J.
    (2011). Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J. Biol. Chem. 286, 36396-36403. doi:10.1074/jbc.M111.257071
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Crabbe, L.,
    2. Jauch, A.,
    3. Naeger, C. M.,
    4. Holtgreve-Grez, H. and
    5. Karlseder, J.
    (2007). Telomere dysfunction as a cause of genomic instability in Werner syndrome. Proc. Natl. Acad. Sci. USA 104, 2205-2210. doi:10.1073/pnas.0609410104
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Croteau, D. L.,
    2. Rossi, M. L.,
    3. Canugovi, C.,
    4. Tian, J.,
    5. Sykora, P.,
    6. Ramamoorthy, M.,
    7. Wang, Z. M.,
    8. Singh, D. K.,
    9. Akbari, M.,
    10. Kasiviswanathan, R. et al.
    (2012). RECQL4 localizes to mitochondria and preserves mitochondrial DNA integrity. Aging Cell 11, 456-466. doi:10.1111/j.1474-9726.2012.00803.x
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Das, A.,
    2. Grotsky, D. A.,
    3. Neumann, M. A.,
    4. Kreienkamp, R.,
    5. Gonzalez-Suarez, I.,
    6. Redwood, A. B.,
    7. Kennedy, B. K.,
    8. Stewart, C. L. and
    9. Gonzalo, S.
    (2013). Lamin A Deltaexon9 mutation leads to telomere and chromatin defects but not genomic instability. Nucleus 4, 410-419. doi:10.4161/nucl.26873
    OpenUrlCrossRefPubMed
  42. ↵
    1. Davis, T.,
    2. Wyllie, F. S.,
    3. Rokicki, M. J.,
    4. Bagley, M. C. and
    5. Kipling, D.
    (2007). The role of cellular senescence in Werner syndrome: toward therapeutic intervention in human premature aging. Ann. N. Y. Acad. Sci. 1100, 455-469. doi:10.1196/annals.1395.051
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. de Boer, J.,
    2. de Wit, J.,
    3. van Steeg, H.,
    4. Berg, R. J. W.,
    5. Morreau, H.,
    6. Visser, P.,
    7. Lehmann, A. R.,
    8. Duran, M.,
    9. Hoeijmakers, J. H. J. and
    10. Weeda, G.
    (1998). A mouse model for the basal transcription/DNA repair syndrome trichothiodystrophy. Mol. Cell 1, 981-990. doi:10.1016/S1097-2765(00)80098-2
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    1. de Cabo, R.,
    2. Carmona-Gutierrez, D.,
    3. Bernier, M.,
    4. Hall, M. N. and
    5. Madeo, F.
    (2014). The search for antiaging interventions: from elixirs to fasting regimens. Cell 157, 1515-1526. doi:10.1016/j.cell.2014.05.031
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. de la Rosa, J.,
    2. Freije, J. M. P.,
    3. Cabanillas, R.,
    4. Osorio, F. G.,
    5. Fraga, M. F.,
    6. Fernández-García, M. S.,
    7. Rad, R.,
    8. Fanjul, V.,
    9. Ugalde, A. P.,
    10. Liang, Q. et al.
    (2013). Prelamin A causes progeria through cell-extrinsic mechanisms and prevents cancer invasion. Nat. Commun. 4, 2268. doi:10.1038/ncomms3268
    OpenUrlCrossRefPubMed
  46. ↵
    1. De Sandre-Giovannoli, A.,
    2. Bernard, R.,
    3. Cau, P.,
    4. Navarro, C.,
    5. Amiel, J.,
    6. Boccaccio, I.,
    7. Lyonnet, S.,
    8. Stewart, C. L.,
    9. Munnich, A.,
    10. Le Merrer, M. et al.
    (2003). Lamin a truncation in Hutchinson-Gilford progeria. Science 300, 2055. doi:10.1126/science.1084125
    OpenUrlFREE Full Text
  47. ↵
    1. Deakyne, J. S. and
    2. Mazin, A. V.
    (2011). Fanconi anemia: at the crossroads of DNA repair. Biochemistry 76, 36-48. doi:10.1134/S0006297911010068
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Dechat, T.,
    2. Shimi, T.,
    3. Adam, S. A.,
    4. Rusinol, A. E.,
    5. Andres, D. A.,
    6. Spielmann, H. P.,
    7. Sinensky, M. S. and
    8. Goldman, R. D.
    (2007). Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc. Natl. Acad. Sci. USA 104, 4955-4960. doi:10.1073/pnas.0700854104
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Decker, M. L.,
    2. Chavez, E.,
    3. Vulto, I. and
    4. Lansdorp, P. M.
    (2009). Telomere length in Hutchinson-Gilford progeria syndrome. Mech. Ageing Dev. 130, 377-383. doi:10.1016/j.mad.2009.03.001
    OpenUrlCrossRefPubMed
  50. ↵
    1. Du, W.,
    2. Amarachintha, S.,
    3. Sipple, J.,
    4. Schick, J.,
    5. Steinbrecher, K. and
    6. Pang, Q.
    (2013). Inflammation-mediated notch signaling skews fanconi anemia hematopoietic stem cell differentiation. J. Immunol. 191, 2806-2817. doi:10.4049/jimmunol.1203474
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Dupuy, A. and
    2. Sarasin, A.
    (2015). DNA damage and gene therapy of xeroderma pigmentosum, a human DNA repair-deficient disease. Mutat. Res. 776, 2-8. doi:10.1016/j.mrfmmm.2014.08.007
    OpenUrlCrossRefPubMed
  52. ↵
    1. Edelman, J. R. and
    2. Lin, Y. J.
    (2001). Translocation of unstable heterochromatin as the mechanism of sister chromatid exchange formation: a proposed hypothesis. Cytobios 106, 171-191.
    OpenUrlPubMed
  53. ↵
    1. Ellis, N. A.,
    2. Sander, M.,
    3. Harris, C. C. and
    4. Bohr, V. A.
    (2008). Bloom's syndrome workshop focuses on the functional specificities of RecQ helicases. Mech. Ageing Dev. 129, 681-691. doi:10.1016/j.mad.2008.09.005
    OpenUrlCrossRefPubMed
  54. ↵
    1. Eriksson, M.,
    2. Brown, W. T.,
    3. Gordon, L. B.,
    4. Glynn, M. W.,
    5. Singer, J.,
    6. Scott, L.,
    7. Erdos, M. R.,
    8. Robbins, C. M.,
    9. Moses, T. Y.,
    10. Berglund, P. et al.
    (2003). Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293-298. doi:10.1038/nature01629
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Espada, J.,
    2. Varela, I.,
    3. Flores, I.,
    4. Ugalde, A. P.,
    5. Cadiñanos, J.,
    6. Pendás, A. M.,
    7. Stewart, C. L.,
    8. Tryggvason, K.,
    9. Blasco, M. A.,
    10. Freije, J. M. P. et al.
    (2008). Nuclear envelope defects cause stem cell dysfunction in premature-aging mice. J. Cell Biol. 181, 27-35. doi:10.1083/jcb.200801096
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Fernandez, P.,
    2. Scaffidi, P.,
    3. Markert, E.,
    4. Lee, J.-H.,
    5. Rane, S. and
    6. Misteli, T.
    (2014). Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4. Cell Rep. 9, 248-260. doi:10.1016/j.celrep.2014.08.069
    OpenUrlCrossRefPubMed
    1. Fernet, M.,
    2. Gribaa, M.,
    3. Salih, M. A. M.,
    4. Seidahmed, M. Z.,
    5. Hall, J. and
    6. Koenig, M.
    (2005). Identification and functional consequences of a novel MRE11 mutation affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like disorder. Hum. Mol. Genet. 14, 307-318. doi:10.1093/hmg/ddi027
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Freije, J. M. P. and
    2. Lopez-Otin, C.
    (2012). Reprogramming aging and progeria. Curr. Opin. Cell Biol. 24, 757-764. doi:10.1016/j.ceb.2012.08.009
    OpenUrlCrossRefPubMed
  58. ↵
    1. Fu, L.,
    2. Xu, X.,
    3. Ren, R.,
    4. Wu, J.,
    5. Zhang, W.,
    6. Yang, J.,
    7. Ren, X.,
    8. Wang, S.,
    9. Zhao, Y.,
    10. Sun, L. et al.
    (2016). Modeling xeroderma pigmentosum associated neurological pathologies with patients-derived iPSCs. Protein Cell 7, 210-221. doi:10.1007/s13238-016-0244-y
    OpenUrlCrossRefPubMed
  59. ↵
    1. Fukawatase, Y.,
    2. Toyoda, M.,
    3. Okamura, K.,
    4. Nakamura, K.-I.,
    5. Nakabayashi, K.,
    6. Takada, S.,
    7. Yamazaki-Inoue, M.,
    8. Masuda, A.,
    9. Nasu, M.,
    10. Hata, K. et al.
    (2014). Ataxia telangiectasia derived iPS cells show preserved x-ray sensitivity and decreased chromosomal instability. Sci. Rep. 4, 5421. doi:10.1038/srep05421
    OpenUrlCrossRefPubMed
  60. ↵
    1. Gerhard-Herman, M.,
    2. Smoot, L. B.,
    3. Wake, N.,
    4. Kieran, M. W.,
    5. Kleinman, M. E.,
    6. Miller, D. T.,
    7. Schwartzman, A.,
    8. Giobbie-Hurder, A.,
    9. Neuberg, D. and
    10. Gordon, L. B.
    (2012). Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension 59, 92-97. doi:10.1161/HYPERTENSIONAHA.111.180919
    OpenUrlCrossRef
  61. ↵
    1. Goldman, R. D.,
    2. Shumaker, D. K.,
    3. Erdos, M. R.,
    4. Eriksson, M.,
    5. Goldman, A. E.,
    6. Gordon, L. B.,
    7. Gruenbaum, Y.,
    8. Khuon, S.,
    9. Mendez, M.,
    10. Varga, R. et al.
    (2004). Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA 101, 8963-8968. doi:10.1073/pnas.0402943101
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Gonzalo, S. and
    2. Kreienkamp, R.
    (2015). DNA repair defects and genome instability in Hutchinson-Gilford Progeria Syndrome. Curr. Opin. Cell Biol. 34, 75-83. doi:10.1016/j.ceb.2015.05.007
    OpenUrlCrossRefPubMed
  63. ↵
    1. Gorbunova, V.,
    2. Seluanov, A.,
    3. Mao, Z. and
    4. Hine, C.
    (2007). Changes in DNA repair during aging. Nucleic Acids Res. 35, 7466-7474. doi:10.1093/nar/gkm756
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Gordon, L. B.,
    2. Kleinman, M. E.,
    3. Miller, D. T.,
    4. Neuberg, D. S.,
    5. Giobbie-Hurder, A.,
    6. Gerhard-Herman, M.,
    7. Smoot, L. B.,
    8. Gordon, C. M.,
    9. Cleveland, R.,
    10. Snyder, B. D. et al.
    (2012). Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA 109, 16666-16671. doi:10.1073/pnas.1202529109
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Gordon, L. B.,
    2. Rothman, F. G.,
    3. López-Otín, C. and
    4. Misteli, T.
    (2014). Progeria: a paradigm for translational medicine. Cell 156, 400-407. doi:10.1016/j.cell.2013.12.028
    OpenUrlCrossRefPubMedWeb of Science
  66. ↵
    1. Goto, M.,
    2. Sugimoto, K.,
    3. Hayashi, S.,
    4. Ogino, T.,
    5. Sugimoto, M.,
    6. Furuichi, Y.,
    7. Matsuura, M.,
    8. Ishikawa, Y.,
    9. Iwaki-Egawa, S. and
    10. Watanabe, Y.
    (2012). Aging-associated inflammation in healthy Japanese individuals and patients with Werner syndrome. Exp. Gerontol. 47, 936-939. doi:10.1016/j.exger.2012.08.010
    OpenUrlCrossRefPubMed
  67. ↵
    1. Griffith, E.,
    2. Walker, S.,
    3. Martin, C.-A.,
    4. Vagnarelli, P.,
    5. Stiff, T.,
    6. Vernay, B.,
    7. Al Sanna, N.,
    8. Saggar, A.,
    9. Hamel, B.,
    10. Earnshaw, W. C. et al.
    (2008). Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling. Nat. Genet. 40, 232-236. doi:10.1038/ng.2007.80
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    1. Gutierrez-Fernandez, A.,
    2. Soria-Valles, C.,
    3. Osorio, F. G.,
    4. Gutierrez-Abril, J.,
    5. Garabaya, C.,
    6. Aguirre, A.,
    7. Fueyo, A.,
    8. Fernandez-Garcia, M. S.,
    9. Puente, X. S. and
    10. Lopez-Otin, C.
    (2015). Loss of MT1-MMP causes cell senescence and nuclear defects which can be reversed by retinoic acid. EMBO J. 34, 1875-1888. doi:10.15252/embj.201490594
    OpenUrlAbstract/FREE Full Text
    1. Hennekam, R. C. M.
    (2006). Hutchinson-Gilford progeria syndrome: review of the phenotype. Am. J. Med. Genet. A 140A, 2603-2624. doi:10.1002/ajmg.a.31346
    OpenUrlCrossRefPubMed
  69. ↵
    1. Hishiya, A.,
    2. Ito, M.,
    3. Aburatani, H.,
    4. Motoyama, N.,
    5. Ikeda, K. and
    6. Watanabe, K.
    (2005). Ataxia telangiectasia mutated (Atm) knockout mice as a model of osteopenia due to impaired bone formation. Bone 37, 497-503. doi:10.1016/j.bone.2005.05.012
    OpenUrlCrossRefPubMed
    1. Ho, J. C. Y.,
    2. Zhou, T.,
    3. Lai, W.-H.,
    4. Huang, Y.,
    5. Chan, Y.-C.,
    6. Li, X.,
    7. Wong, N. L. Y.,
    8. Li, Y.,
    9. Au, K.-W.,
    10. Guo, D. et al.
    (2011). Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging 3, 380-390. doi:10.18632/aging.100277
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    1. Hockemeyer, D.,
    2. Palm, W.,
    3. Wang, R. C.,
    4. Couto, S. S. and
    5. de Lange, T.
    (2008). Engineered telomere degradation models dyskeratosis congenita. Genes Dev. 22, 1773-1785. doi:10.1101/gad.1679208
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Hong, H.,
    2. Takahashi, K.,
    3. Ichisaka, T.,
    4. Aoi, T.,
    5. Kanagawa, O.,
    6. Nakagawa, M.,
    7. Okita, K. and
    8. Yamanaka, S.
    (2009). Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-1135. doi:10.1038/nature08235
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    1. Hosseini, M.,
    2. Mahfouf, W.,
    3. Serrano-Sanchez, M.,
    4. Raad, H.,
    5. Harfouche, G.,
    6. Bonneu, M.,
    7. Claverol, S.,
    8. Mazurier, F.,
    9. Rossignol, R.,
    10. Taieb, A. et al.
    (2015). Premature skin aging features rescued by inhibition of NADPH oxidase activity in XPC-deficient mice. J. Invest. Dermatol. 135, 1108-1118. doi:10.1038/jid.2014.511
    OpenUrlCrossRefPubMed
    1. Houghtaling, S.,
    2. Timmers, C.,
    3. Noll, M.,
    4. Finegold, M. J.,
    5. Jones, S. N.,
    6. Meyn, M. S. and
    7. Grompe, M.
    (2003). Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 17, 2021-2035. doi:10.1101/gad.1103403
    OpenUrlAbstract/FREE Full Text
    1. Huang, S.,
    2. Lee, L.,
    3. Hanson, N. B.,
    4. Lenaerts, C.,
    5. Hoehn, H.,
    6. Poot, M.,
    7. Rubin, C. D.,
    8. Chen, D.-F.,
    9. Yang, C.-C.,
    10. Juch, H. et al.
    (2006). The spectrum of WRN mutations in Werner syndrome patients. Hum. Mutat. 27, 558-567. doi:10.1002/humu.20337
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    1. Ibrahim, M. X.,
    2. Sayin, V. I.,
    3. Akula, M. K.,
    4. Liu, M.,
    5. Fong, L. G.,
    6. Young, S. G. and
    7. Bergo, M. O.
    (2013). Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science 340, 1330-1333. doi:10.1126/science.1238880
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Itin, P. H.,
    2. Sarasin, A. and
    3. Pittelkow, M. R.
    (2001). Trichothiodystrophy: update on the sulfur-deficient brittle hair syndromes. J. Am. Acad. Dermatol. 44, 891-924; quiz 921-924. doi:10.1067/mjd.2001.114294
    OpenUrlCrossRefPubMedWeb of Science
  75. ↵
    1. Jaarsma, D.,
    2. van der Pluijm, I.,
    3. van der Horst, G. T. J. and
    4. Hoeijmakers, J. H. J.
    (2013). Cockayne syndrome pathogenesis: lessons from mouse models. Mech. Ageing Dev. 134, 180-195. doi:10.1016/j.mad.2013.04.003
    OpenUrlCrossRefPubMed
  76. ↵
    1. Jamin, A. and
    2. Wiebe, M. S.
    (2015). Barrier to Autointegration Factor (BANF1): interwoven roles in nuclear structure, genome integrity, innate immunity, stress responses and progeria. Curr. Opin. Cell Biol. 34, 61-68. doi:10.1016/j.ceb.2015.05.006
    OpenUrlCrossRefPubMed
  77. ↵
    1. Jung, H.-J.,
    2. Coffinier, C.,
    3. Choe, Y.,
    4. Beigneux, A. P.,
    5. Davies, B. S. J.,
    6. Yang, S. H.,
    7. Barnes, R. H., II.,
    8. Hong, J.,
    9. Sun, T.,
    10. Pleasure, S. J. et al.
    (2012). Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. Proc. Natl. Acad. Sci. USA 109, E423-E431. doi:10.1073/pnas.1111780109
    OpenUrlAbstract/FREE Full Text
  78. ↵
    1. Jurk, D.,
    2. Wilson, C.,
    3. Passos, J. F.,
    4. Oakley, F.,
    5. Correia-Melo, C.,
    6. Greaves, L.,
    7. Saretzki, G.,
    8. Fox, C.,
    9. Lawless, C.,
    10. Anderson, R. et al.
    (2014). Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat. Commun. 2, 4172. doi:10.1038/ncomms5172
    OpenUrlCrossRefPubMed
  79. ↵
    1. Karakasilioti, I.,
    2. Kamileri, I.,
    3. Chatzinikolaou, G.,
    4. Kosteas, T.,
    5. Vergadi, E.,
    6. Robinson, A. R.,
    7. Tsamardinos, I.,
    8. Rozgaja, T. A.,
    9. Siakouli, S.,
    10. Tsatsanis, C. et al.
    (2013). DNA damage triggers a chronic autoinflammatory response, leading to fat depletion in NER progeria. Cell Metab. 18, 403-415. doi:10.1016/j.cmet.2013.08.011
    OpenUrlCrossRefPubMedWeb of Science
  80. ↵
    1. Kennedy, B. K.,
    2. Berger, S. L.,
    3. Brunet, A.,
    4. Campisi, J.,
    5. Cuervo, A. M.,
    6. Epel, E. S.,
    7. Franceschi, C.,
    8. Lithgow, G. J.,
    9. Morimoto, R. I.,
    10. Pessin, J. E. et al.
    (2014). Geroscience: linking aging to chronic disease. Cell 159, 709-713. doi:10.1016/j.cell.2014.10.039
    OpenUrlCrossRefPubMed
  81. ↵
    1. Kocak, H.,
    2. Ballew, B. J.,
    3. Bisht, K.,
    4. Eggebeen, R.,
    5. Hicks, B. D.,
    6. Suman, S.,
    7. O'Neil, A.,
    8. Giri, N.,
    9. Maillard, I.,
    10. Alter, B. P. et al.
    (2014). Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1. Genes Dev. 28, 2090-2102. doi:10.1101/gad.248567.114
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Krishnan, V.,
    2. Chow, M. Z. Y.,
    3. Wang, Z.,
    4. Zhang, L.,
    5. Liu, B.,
    6. Liu, X. and
    7. Zhou, Z.
    (2011). Histone H4 lysine 16 hypoacetylation is associated with defective DNA repair and premature senescence in Zmpste24-deficient mice. Proc. Natl. Acad. Sci. USA 108, 12325-12330. doi:10.1073/pnas.1102789108
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Kudlow, B. A.,
    2. Stanfel, M. N.,
    3. Burtner, C. R.,
    4. Johnston, E. D. and
    5. Kennedy, B. K.
    (2008). Suppression of proliferative defects associated with processing-defective lamin A mutants by hTERT or inactivation of p53. Mol. Biol. Cell 19, 5238-5248. doi:10.1091/mbc.E08-05-0492
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Kuschal, C.,
    2. Khan, S. G.,
    3. Enk, B.,
    4. DiGiovanna, J. J. and
    5. Kraemer, K. H.
    (2015). Readthrough of stop codons by use of aminoglycosides in cells from xeroderma pigmentosum group C patients. Exp. Dermatol. 24, 296-297. doi:10.1111/exd.12655
    OpenUrlCrossRefPubMed
  85. ↵
    1. Labbe, A.,
    2. Garand, C.,
    3. Cogger, V. C.,
    4. Paquet, E. R.,
    5. Desbiens, M.,
    6. Le Couteur, D. G. and
    7. Lebel, M.
    (2011). Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome. J. Gerontol. A Biol. Sci. Med. Sci. 66A, 264-278. doi:10.1093/gerona/glq184
    OpenUrlCrossRefPubMedWeb of Science
  86. ↵
    1. Langevin, F.,
    2. Crossan, G. P.,
    3. Rosado, I. V.,
    4. Arends, M. J. and
    5. Patel, K. J.
    (2011). Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 475, 53-58. doi:10.1038/nature10192
    OpenUrlCrossRefPubMedWeb of Science
  87. ↵
    1. Larrieu, D.,
    2. Britton, S.,
    3. Demir, M.,
    4. Rodriguez, R. and
    5. Jackson, S. P.
    (2014). Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science 344, 527-532. doi:10.1126/science.1252651
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Lavasani, M.,
    2. Robinson, A. R.,
    3. Lu, A.,
    4. Song, M.,
    5. Feduska, J. M.,
    6. Ahani, B.,
    7. Tilstra, J. S.,
    8. Feldman, C. H.,
    9. Robbins, P. D.,
    10. Niedernhofer, L. J. et al.
    (2012). Muscle-derived stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model. Nat. Commun. 3, 608. doi:10.1038/ncomms1611
    OpenUrlCrossRefPubMed
  89. ↵
    1. Lebel, M. and
    2. Leder, P.
    (1998). A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc. Natl. Acad. Sci. USA 95, 13097-13102. doi:10.1073/pnas.95.22.13097
    OpenUrlAbstract/FREE Full Text
  90. ↵
    1. Li, H.,
    2. Collado, M.,
    3. Villasante, A.,
    4. Strati, K.,
    5. Ortega, S.,
    6. Cañamero, M.,
    7. Blasco, M. A. and
    8. Serrano, M.
    (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136-1139. doi:10.1038/nature08290
    OpenUrlCrossRefPubMedWeb of Science
  91. ↵
    1. Liao, C.-Y. and
    2. Kennedy, B. K.
    (2014). Mouse models and aging: longevity and progeria. Curr. Top. Dev. Biol. 109, 249-285. doi:10.1016/B978-0-12-397920-9.00003-2
    OpenUrlCrossRefPubMed
  92. ↵
    1. Liu, B.,
    2. Wang, J.,
    3. Chan, K. M.,
    4. Tjia, W. M.,
    5. Deng, W.,
    6. Guan, X.,
    7. Huang, J.-D.,
    8. Li, K. M.,
    9. Chau, P. Y.,
    10. Chen, D. J. et al.
    (2005). Genomic instability in laminopathy-based premature aging. Nat. Med. 11, 780-785. doi:10.1038/nm1266
    OpenUrlCrossRefPubMedWeb of Science
    1. Liu, G.-H.,
    2. Barkho, B. Z.,
    3. Ruiz, S.,
    4. Diep, D.,
    5. Qu, J.,
    6. Yang, S.-L.,
    7. Panopoulos, A. D.,
    8. Suzuki, K.,
    9. Kurian, L.,
    10. Walsh, C. et al.
    (2011). Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472, 221-225. doi:10.1038/nature09879
    OpenUrlCrossRefPubMedWeb of Science
  93. ↵
    1. Liu, B.,
    2. Ghosh, S.,
    3. Yang, X.,
    4. Zheng, H.,
    5. Liu, X.,
    6. Wang, Z.,
    7. Jin, G.,
    8. Zheng, B.,
    9. Kennedy, B. K.,
    10. Suh, Y. et al.
    (2012). Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria. Cell Metab. 16, 738-750. doi:10.1016/j.cmet.2012.11.007
    OpenUrlCrossRefPubMedWeb of Science
  94. ↵
    1. Liu, B.,
    2. Wang, Z.,
    3. Zhang, L.,
    4. Ghosh, S.,
    5. Zheng, H. and
    6. Zhou, Z.
    (2013). Depleting the methyltransferase Suv39h1 improves DNA repair and extends lifespan in a progeria mouse model. Nat. Commun. 4, 1868. doi:10.1038/ncomms2885
    OpenUrlCrossRefPubMed
  95. ↵
    1. Lo Cicero, A. and
    2. Nissan, X.
    (2015). Pluripotent stem cells to model Hutchinson-Gilford progeria syndrome (HGPS): current trends and future perspectives for drug discovery. Ageing Res. Rev. 24, 343-348. doi:10.1016/j.arr.2015.10.002
    OpenUrlCrossRefPubMed
  96. ↵
    1. Loi, M.,
    2. Cenni, V.,
    3. Duchi, S.,
    4. Squarzoni, S.,
    5. Lopez-Otin, C.,
    6. Foisner, R.,
    7. Lattanzi, G. and
    8. Capanni, C.
    (2016). Barrier-to-Autointegration Factor (BAF) involvement in prelamin A-related chromatin organization changes. Oncotarget. 7, 15662-15677. doi:10.18632/oncotarget.6697
    OpenUrlCrossRefPubMed
  97. ↵
    1. Lombard, D. B.,
    2. Beard, C.,
    3. Johnson, B.,
    4. Marciniak, R. A.,
    5. Dausman, J.,
    6. Bronson, R.,
    7. Buhlmann, J. E.,
    8. Lipman, R.,
    9. Curry, R.,
    10. Sharpe, A. et al.
    (2000). Mutations in the WRN gene in mice accelerate mortality in a p53-null background. Mol. Cell. Biol. 20, 3286-3291. doi:10.1128/MCB.20.9.3286-3291.2000
    OpenUrlAbstract/FREE Full Text
  98. ↵
    1. Lopez-Otin, C.,
    2. Blasco, M. A.,
    3. Partridge, L.,
    4. Serrano, M. and
    5. Kroemer, G.
    (2013). The hallmarks of aging. Cell 153, 1194-1217. doi:10.1016/j.cell.2013.05.039
    OpenUrlCrossRefPubMedWeb of Science
  99. ↵
    1. Lu, H.,
    2. Fang, E. F.,
    3. Sykora, P.,
    4. Kulikowicz, T.,
    5. Zhang, Y.,
    6. Becker, K. G.,
    7. Croteau, D. L. and
    8. Bohr, V. A.
    (2014). Senescence induced by RECQL4 dysfunction contributes to Rothmund-Thomson syndrome features in mice. Cell Death Dis. 5, e1226. doi:10.1038/cddis.2014.168
    OpenUrlCrossRefPubMed
  100. ↵
    1. Luo, G.,
    2. Santoro, I. M.,
    3. McDaniel, L. D.,
    4. Nishijima, I.,
    5. Mills, M.,
    6. Youssoufian, H.,
    7. Vogel, H.,
    8. Schultz, R. A. and
    9. Bradley, A.
    (2000). Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nat. Genet. 26, 424-429. doi:10.1038/82548
    OpenUrlCrossRefPubMedWeb of Science
  101. ↵
    1. Machwe, A.,
    2. Xiao, L.,
    3. Groden, J.,
    4. Matson, S. W. and
    5. Orren, D. K.
    (2005). RecQ family members combine strand pairing and unwinding activities to catalyze strand exchange. J. Biol. Chem. 280, 23397-23407. doi:10.1074/jbc.M414130200
    OpenUrlAbstract/FREE Full Text
  102. ↵
    1. Mann, M. B.,
    2. Hodges, C. A.,
    3. Barnes, E.,
    4. Vogel, H.,
    5. Hassold, T. J. and
    6. Luo, G.
    (2005). Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. Hum. Mol. Genet. 14, 813-825. doi:10.1093/hmg/ddi075
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Marino, G.,
    2. Ugalde, A. P.,
    3. Salvador-Montoliu, N.,
    4. Varela, I.,
    5. Quiros, P. M.,
    6. Cadinanos, J.,
    7. van der Pluijm, I.,
    8. Freije, J. M. P. and
    9. Lopez-Otin, C.
    (2008). Premature aging in mice activates a systemic metabolic response involving autophagy induction. Hum. Mol. Genet. 17, 2196-2211. doi:10.1093/hmg/ddn120
    OpenUrlAbstract/FREE Full Text
  104. ↵
    1. Marino, G.,
    2. Ugalde, A. P.,
    3. Fernandez, A. F.,
    4. Osorio, F. G.,
    5. Fueyo, A.,
    6. Freije, J. M. P. and
    7. Lopez-Otin, C.
    (2010). Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. Proc. Natl. Acad. Sci. USA 107, 16268-16273. doi:10.1073/pnas.1002696107
    OpenUrlAbstract/FREE Full Text
  105. ↵
    1. Marteijn, J. A.,
    2. Lans, H.,
    3. Vermeulen, W. and
    4. Hoeijmakers, J. H. J.
    (2014). Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell Biol. 15, 465-481. doi:10.1038/nrm3822
    OpenUrlCrossRefPubMed
  106. ↵
    1. Melis, J. P. M.,
    2. Wijnhoven, S. W. P.,
    3. Beems, R. B.,
    4. Roodbergen, M.,
    5. van den Berg, J.,
    6. Moon, H.,
    7. Friedberg, E.,
    8. van der Horst, G. T. J.,
    9. Hoeijmakers, J. H. J.,
    10. Vijg, J. et al.
    (2008). Mouse models for xeroderma pigmentosum group A and group C show divergent cancer phenotypes. Cancer Res. 68, 1347-1353. doi:10.1158/0008-5472.CAN-07-6067
    OpenUrlAbstract/FREE Full Text
  107. ↵
    1. Missios, P.,
    2. Zhou, Y.,
    3. Guachalla, L. M.,
    4. von Figura, G.,
    5. Wegner, A.,
    6. Chakkarappan, S. R.,
    7. Binz, T.,
    8. Gompf, A.,
    9. Hartleben, G.,
    10. Burkhalter, M. D. et al.
    (2014). Glucose substitution prolongs maintenance of energy homeostasis and lifespan of telomere dysfunctional mice. Nat. Commun. 5, 4924. doi:10.1038/ncomms5924
    OpenUrlCrossRefPubMed
  108. ↵
    1. Muller, L. U. W.,
    2. Milsom, M. D.,
    3. Harris, C. E.,
    4. Vyas, R.,
    5. Brumme, K. M.,
    6. Parmar, K.,
    7. Moreau, L. A.,
    8. Schambach, A.,
    9. Park, I.-H.,
    10. London, W. B. et al.
    (2012). Overcoming reprogramming resistance of Fanconi anemia cells. Blood 119, 5449-5457. doi:10.1182/blood-2012-02-408674
    OpenUrlAbstract/FREE Full Text
  109. ↵
    1. Murga, M.,
    2. Bunting, S.,
    3. Montaña, M. F.,
    4. Soria, R.,
    5. Mulero, F.,
    6. Cañamero, M.,
    7. Lee, Y.,
    8. McKinnon, P. J.,
    9. Nussenzweig, A. and
    10. Fernandez-Capetillo, O.
    (2009). A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat. Genet. 41, 891-898. doi:10.1038/ng.420
    OpenUrlCrossRefPubMedWeb of Science
  110. ↵
    1. Navarro, C. L.,
    2. Cadinanos, J.,
    3. De Sandre-Giovannoli, A.,
    4. Bernard, R.,
    5. Courrier, S.,
    6. Boccaccio, I.,
    7. Boyer, A.,
    8. Kleijer, W. J.,
    9. Wagner, A.,
    10. Giuliano, F. et al.
    (2005). Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum. Mol. Genet. 14, 1503-1513. doi:10.1093/hmg/ddi159
    OpenUrlAbstract/FREE Full Text
  111. ↵
    1. Nayler, S.,
    2. Gatei, M.,
    3. Kozlov, S.,
    4. Gatti, R.,
    5. Mar, J. C.,
    6. Wells, C. A.,
    7. Lavin, M. and
    8. Wolvetang, E.
    (2012). Induced pluripotent stem cells from ataxia-telangiectasia recapitulate the cellular phenotype. Stem Cells Transl. Med. 1, 523-535. doi:10.5966/sctm.2012-0024
    OpenUrlAbstract/FREE Full Text
  112. ↵
    1. Niedernhofer, L. J.,
    2. Garinis, G. A.,
    3. Raams, A.,
    4. Lalai, A. S.,
    5. Robinson, A. R.,
    6. Appeldoorn, E.,
    7. Odijk, H.,
    8. Oostendorp, R.,
    9. Ahmad, A.,
    10. van Leeuwen, W. et al.
    (2006). A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444, 1038-1043. doi:10.1038/nature05456
    OpenUrlCrossRefPubMedWeb of Science
    1. Nissan, X.,
    2. Blondel, S.,
    3. Navarro, C.,
    4. Maury, Y.,
    5. Denis, C.,
    6. Girard, M.,
    7. Martinat, C.,
    8. De Sandre-Giovannoli, A.,
    9. Levy, N. and
    10. Peschanski, M.
    (2012). Unique preservation of neural cells in Hutchinson- Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA. Cell Rep. 2, 1-9. doi:10.1016/j.celrep.2012.05.015
    OpenUrlCrossRefPubMedWeb of Science
  113. ↵
    1. Novelli, G.,
    2. Muchir, A.,
    3. Sangiuolo, F.,
    4. Helbling-Leclerc, A.,
    5. D'Apice, M. R.,
    6. Massart, C.,
    7. Capon, F.,
    8. Sbraccia, P.,
    9. Federici, M.,
    10. Lauro, R. et al.
    (2002). Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am. J. Hum. Genet. 71, 426-431. doi:10.1086/341908
    OpenUrlCrossRefPubMedWeb of Science
  114. ↵
    1. Ohnishi, H.,
    2. Kawasaki, T.,
    3. Deguchi, T. and
    4. Yuba, S.
    (2015). Generation of xeroderma pigmentosum-A patient-derived induced pluripotent stem cell line for use as future disease model. Cell Reprog. 17, 268-274. doi:10.1089/cell.2014.0104
    OpenUrlCrossRef
  115. ↵
    1. Olive, M.,
    2. Harten, I.,
    3. Mitchell, R.,
    4. Beers, J. K.,
    5. Djabali, K.,
    6. Cao, K.,
    7. Erdos, M. R.,
    8. Blair, C.,
    9. Funke, B.,
    10. Smoot, L. et al.
    (2010). Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler. Thromb. Vasc. Biol. 30, 2301-2309. doi:10.1161/ATVBAHA.110.209460
    OpenUrlAbstract/FREE Full Text
  116. ↵
    1. Osorio, F. G.,
    2. Obaya, A. J.,
    3. López-Otín, C. and
    4. Freije, J. M. P.
    (2009). Accelerated ageing: from mechanism to therapy through animal models. Transgenic Res. 18, 7-15. doi:10.1007/s11248-008-9226-z
    OpenUrlCrossRefPubMedWeb of Science
  117. ↵
    1. Osorio, F. G.,
    2. Varela, I.,
    3. Lara, E.,
    4. Puente, X. S.,
    5. Espada, J.,
    6. Santoro, R.,
    7. Freije, J. M. P.,
    8. Fraga, M. F. and
    9. López-Otín, C.
    (2010). Nuclear envelope alterations generate an aging-like epigenetic pattern in mice deficient in Zmpste24 metalloprotease. Aging Cell 9, 947-957. doi:10.1111/j.1474-9726.2010.00621.x
    OpenUrlCrossRefPubMedWeb of Science
  118. ↵
    1. Osorio, F. G.,
    2. Navarro, C. L.,
    3. Cadinanos, J.,
    4. Lopez-Mejia, I. C.,
    5. Quiros, P. M.,
    6. Bartoli, C.,
    7. Rivera, J.,
    8. Tazi, J.,
    9. Guzman, G.,
    10. Varela, I. et al.
    (2011). Splicing-directed therapy in a new mouse model of human accelerated aging. Sci. Transl. Med. 3, 106ra107. doi:10.1126/scitranslmed.3002847
    OpenUrlAbstract/FREE Full Text
  119. ↵
    1. Osorio, F. G.,
    2. Barcena, C.,
    3. Soria-Valles, C.,
    4. Ramsay, A. J.,
    5. de Carlos, F.,
    6. Cobo, J.,
    7. Fueyo, A.,
    8. Freije, J. M. P. and
    9. Lopez-Otin, C.
    (2012). Nuclear lamina defects cause ATM-dependent NF-kappaB activation and link accelerated aging to a systemic inflammatory response. Genes Dev. 26, 2311-2324. doi:10.1101/gad.197954.112
    OpenUrlAbstract/FREE Full Text
  120. ↵
    1. Pacheco, L. M.,
    2. Gomez, L. A.,
    3. Dias, J.,
    4. Ziebarth, N. M.,
    5. Howard, G. A. and
    6. Schiller, P. C.
    (2014). Progerin expression disrupts critical adult stem cell functions involved in tissue repair. Aging 6, 1049-1063. doi:10.18632/aging.100709
    OpenUrlCrossRefPubMed
  121. ↵
    1. Palacios, J. A.,
    2. Herranz, D.,
    3. De Bonis, M. L.,
    4. Velasco, S.,
    5. Serrano, M. and
    6. Blasco, M. A.
    (2010). SIRT1 contributes to telomere maintenance and augments global homologous recombination. J. Cell Biol. 191, 1299-1313. doi:10.1083/jcb.201005160
    OpenUrlAbstract/FREE Full Text
  122. ↵
    1. Paquet, N.,
    2. Box, J. K.,
    3. Ashton, N. W.,
    4. Suraweera, A.,
    5. Croft, L. V.,
    6. Urquhart, A. J.,
    7. Bolderson, E.,
    8. Zhang, S.-D.,
    9. O'Byrne, K. J. and
    10. Richard, D. J.
    (2014). Néstor-Guillermo Progeria Syndrome: a biochemical insight into Barrier-to-Autointegration Factor 1, alanine 12 threonine mutation. BMC Mol. Biol. 15, 27. doi:10.1186/s12867-014-0027-z
    OpenUrlCrossRefPubMed
  123. ↵
    1. Pendas, A. M.,
    2. Zhou, Z.,
    3. Cadinanos, J.,
    4. Freije, J. M.,
    5. Wang, J.,
    6. Hultenby, K.,
    7. Astudillo, A.,
    8. Wernerson, A.,
    9. Rodriguez, F.,
    10. Tryggvason, K. et al.
    (2002). Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat. Genet. 31, 94-99. doi:10.1038/ng871
    OpenUrlCrossRefPubMedWeb of Science
  124. ↵
    1. Pennarun, G.,
    2. Hoffschir, F.,
    3. Revaud, D.,
    4. Granotier, C.,
    5. Gauthier, L. R.,
    6. Mailliet, P.,
    7. Biard, D. S. and
    8. Boussin, F. D.
    (2010). ATR contributes to telomere maintenance in human cells. Nucleic Acids Res. 38, 2955-2963. doi:10.1093/nar/gkp1248
    OpenUrlAbstract/FREE Full Text
  125. ↵
    1. Pitrez, P. R.,
    2. Rosa, S. C.,
    3. Praca, C. and
    4. Ferreira, L.
    (2016). Vascular disease modeling using induced pluripotent stem cells: focus in Hutchinson-Gilford Progeria Syndrome. Biochem. Biophys. Res. Commun. 473, 710-718. doi:10.1016/j.bbrc.2015.10.014
    OpenUrlCrossRefPubMed
  126. ↵
    1. Poitelon, Y.,
    2. Kozlov, S.,
    3. Devaux, J.,
    4. Vallat, J.-M.,
    5. Jamon, M.,
    6. Roubertoux, P.,
    7. Rabarimeriarijaona, S.,
    8. Baudot, C.,
    9. Hamadouche, T.,
    10. Stewart, C. L. et al.
    (2012). Behavioral and molecular exploration of the AR-CMT2A mouse model Lmna (R298C/R298C). Neuromol. Med. 14, 40-52. doi:10.1007/s12017-012-8168-z
    OpenUrlCrossRef
  127. ↵
    1. Pollina, E. A. and
    2. Brunet, A.
    (2011). Epigenetic regulation of aging stem cells. Oncogene 30, 3105-3126. doi:10.1038/onc.2011.45
    OpenUrlCrossRefPubMedWeb of Science
  128. ↵
    1. Puente, X. S.,
    2. Quesada, V.,
    3. Osorio, F. G.,
    4. Cabanillas, R.,
    5. Cadiñanos, J.,
    6. Fraile, J. M.,
    7. Ordóñez, G. R.,
    8. Puente, D. A.,
    9. Gutiérrez-Fernández, A.,
    10. Fanjul-Fernández, M. et al.
    (2011). Exome sequencing and functional analysis identifies BANF1 mutation as the cause of a hereditary progeroid syndrome. Am. J. Hum. Genet. 88, 650-656. doi:10.1016/j.ajhg.2011.04.010
    OpenUrlCrossRefPubMedWeb of Science
  129. ↵
    1. Puzianowska-Kuznicka, M. and
    2. Kuznicki, J.
    (2005). Genetic alterations in accelerated ageing syndromes: do they play a role in natural ageing? Int. J. Biochem. Cell Biol. 37, 947-960. doi:10.1016/j.biocel.2004.10.011
    OpenUrlCrossRefPubMedWeb of Science
  130. ↵
    1. Rando, T. A. and
    2. Chang, H. Y.
    (2012). Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. Cell 148, 46-57. doi:10.1016/j.cell.2012.01.003
    OpenUrlCrossRefPubMedWeb of Science
  131. ↵
    1. Raya, A.,
    2. Rodríguez-Pizà, I.,
    3. Guenechea, G.,
    4. Vassena, R.,
    5. Navarro, S.,
    6. Barrero, M. J.,
    7. Consiglio, A.,
    8. Castellà, M.,
    9. Rio, P.,
    10. Sleep, E. et al.
    (2009). Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460, 53-59. doi:10.1038/nature08129
    OpenUrlCrossRefPubMedWeb of Science
  132. ↵
    1. Righolt, C. H.,
    2. van ‘t Hoff, M. L. R.,
    3. Vermolen, B. J.,
    4. Young, I. T. and
    5. Raz, V.
    (2011). Robust nuclear lamina-based cell classification of aging and senescent cells. Aging 3, 1192-1201. doi:10.18632/aging.100414
    OpenUrlCrossRefPubMed
  133. ↵
    1. Rivera-Torres, J.,
    2. Acín-Perez, R.,
    3. Cabezas-Sánchez, P.,
    4. Osorio, F. G.,
    5. Gonzalez-Gómez, C.,
    6. Megias, D.,
    7. Cámara, C.,
    8. López-Otín, C.,
    9. Enríquez, J. A.,
    10. Luque-Garcia, J. L. et al.
    (2013). Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture. J. Proteomics 91, 466-477. doi:10.1016/j.jprot.2013.08.008
    OpenUrlCrossRefPubMed
  134. ↵
    1. Roos, C. M.,
    2. Zhang, B.,
    3. Palmer, A. K.,
    4. Ogrodnik, M. B.,
    5. Pirtskhalava, T.,
    6. Thalji, N. M.,
    7. Hagler, M.,
    8. Jurk, D.,
    9. Smith, L. A.,
    10. Casaclang-Verzosa, G. et al.
    (2016). Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell. [Epub ahead of print] doi:10.1111/acel.12458
    OpenUrlCrossRef
  135. ↵
    1. Rosengardten, Y.,
    2. McKenna, T.,
    3. Grochová, D. and
    4. Eriksson, M.
    (2011). Stem cell depletion in Hutchinson-Gilford progeria syndrome. Aging Cell 10, 1011-1020. doi:10.1111/j.1474-9726.2011.00743.x
    OpenUrlCrossRefPubMedWeb of Science
  136. ↵
    1. Saadatzadeh, M. R.,
    2. Bijangi-Vishehsaraei, K.,
    3. Kapur, R. and
    4. Haneline, L. S.
    (2009). Distinct roles of stress-activated protein kinases in Fanconi anemia-type C-deficient hematopoiesis. Blood 113, 2655-2660. doi:10.1182/blood-2008-09-181420
    OpenUrlAbstract/FREE Full Text
  137. ↵
    1. Sahin, E. and
    2. DePinho, R. A.
    (2010). Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 464, 520-528. doi:10.1038/nature08982
    OpenUrlCrossRefPubMedWeb of Science
  138. ↵
    1. Salminen, A.,
    2. Kaarniranta, K. and
    3. Kauppinen, A.
    (2012). Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging 4, 166-175. doi:10.18632/aging.100444
    OpenUrlCrossRefPubMed
  139. ↵
    1. Scaffidi, P. and
    2. Misteli, T.
    (2005). Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat. Med. 11, 440-445. doi:10.1038/nm1204
    OpenUrlCrossRefPubMedWeb of Science
  140. ↵
    1. Scaffidi, P. and
    2. Misteli, T.
    (2006). Lamin A-dependent nuclear defects in human aging. Science 312, 1059-1063. doi:10.1126/science.1127168
    OpenUrlAbstract/FREE Full Text
  141. ↵
    1. Scaffidi, P. and
    2. Misteli, T.
    (2008). Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat. Cell Biol. 10, 452-459. doi:10.1038/ncb1708
    OpenUrlCrossRefPubMedWeb of Science
  142. ↵
    1. Scheibye-Knudsen, M.,
    2. Croteau, D. L. and
    3. Bohr, V. A.
    (2013). Mitochondrial deficiency in Cockayne syndrome. Mech. Ageing Dev. 134, 275-283. doi:10.1016/j.mad.2013.02.007
    OpenUrlCrossRefPubMed
  143. ↵
    1. Scheibye-Knudsen, M.,
    2. Mitchell, S. J.,
    3. Fang, E. F.,
    4. Iyama, T.,
    5. Ward, T.,
    6. Wang, J.,
    7. Dunn, C. A.,
    8. Singh, N.,
    9. Veith, S.,
    10. Hasan-Olive, M. M. et al.
    (2014). A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 20, 840-855. doi:10.1016/j.cmet.2014.10.005
    OpenUrlCrossRefPubMed
  144. ↵
    1. Schumacher, B.,
    2. Hoeijmakers, J. H. and
    3. Garinis, G. A.
    (2009). Sealing the gap between nuclear DNA damage and longevity. Mol. Cell. Endocrinol. 299, 112-117. doi:10.1016/j.mce.2008.10.031
    OpenUrlCrossRefPubMedWeb of Science
    1. Seemanova, E.,
    2. Sperling, K.,
    3. Neitzel, H.,
    4. Varon, R.,
    5. Hadac, J.,
    6. Butova, O.,
    7. Schrock, E.,
    8. Seeman, P. and
    9. Digweed, M.
    (2006). Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability. J. Med. Genet. 43, 218-224. doi:10.1136/jmg.2005.035287
    OpenUrlAbstract/FREE Full Text
  145. ↵
    1. Shanske, A.,
    2. Caride, D. G.,
    3. Menasse-Palmer, L.,
    4. Bogdanow, A. and
    5. Marion, R. W.
    (1997). Central nervous system anomalies in Seckel syndrome: report of a new family and review of the literature. Am. J. Med. Genet. 70, 155-158. doi:10.1002/(SICI)1096-8628(19970516)70:2<155::AID-AJMG10>3.0.CO;2-I
    OpenUrlCrossRefPubMed
  146. ↵
    1. Sharma, G. G.,
    2. So, S.,
    3. Gupta, A.,
    4. Kumar, R.,
    5. Cayrou, C.,
    6. Avvakumov, N.,
    7. Bhadra, U.,
    8. Pandita, R. K.,
    9. Porteus, M. H.,
    10. Chen, D. J. et al.
    (2010). MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol. Cell. Biol. 30, 3582-3595. doi:10.1128/MCB.01476-09
    OpenUrlAbstract/FREE Full Text
  147. ↵
    1. Shimamoto, A.,
    2. Kagawa, H.,
    3. Zensho, K.,
    4. Sera, Y.,
    5. Kazuki, Y.,
    6. Osaki, M.,
    7. Oshimura, M.,
    8. Ishigaki, Y.,
    9. Hamasaki, K.,
    10. Kodama, Y. et al.
    (2014). Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. PLoS ONE 9, e112900. doi:10.1371/journal.pone.0112900
    OpenUrlCrossRefPubMed
  148. ↵
    1. Shumaker, D. K.,
    2. Dechat, T.,
    3. Kohlmaier, A.,
    4. Adam, S. A.,
    5. Bozovsky, M. R.,
    6. Erdos, M. R.,
    7. Eriksson, M.,
    8. Goldman, A. E.,
    9. Khuon, S.,
    10. Collins, F. S. et al.
    (2006). Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc. Natl. Acad. Sci. USA 103, 8703-8708. doi:10.1073/pnas.0602569103
    OpenUrlAbstract/FREE Full Text
    1. Singh, L.,
    2. Brennan, T. A.,
    3. Kim, J.-H.,
    4. Egan, K. P.,
    5. McMillan, E. A.,
    6. Chen, Q.,
    7. Hankenson, K. D.,
    8. Zhang, Y.,
    9. Emerson, S. G.,
    10. Johnson, F. B. et al.
    (2013). Long-term functional engraftment of mesenchymal progenitor cells in a mouse model of accelerated aging. Stem Cells 31, 607-611. doi:10.1002/stem.1294
    OpenUrlCrossRefPubMed
  149. ↵
    1. Soria-Valles, C.,
    2. Osorio, F. G.,
    3. Gutierrez-Fernandez, A.,
    4. De Los Angeles, A.,
    5. Bueno, C.,
    6. Menendez, P.,
    7. Martin-Subero, J. I.,
    8. Daley, G. Q.,
    9. Freije, J. M. P. and
    10. Lopez-Otin, C.
    (2015a). NF-kappaB activation impairs somatic cell reprogramming in ageing. Nat. Cell Biol. 17, 1004-1013. doi:10.1038/ncb3207
    OpenUrlCrossRefPubMed
  150. ↵
    1. Soria-Valles, C.,
    2. Osorio, F. G. and
    3. López-Otín, C.
    (2015b). Reprogramming aging through DOT1L inhibition. Cell Cycle 14, 3345-3346. doi:10.1080/15384101.2015.1093443
    OpenUrlCrossRefPubMed
  151. ↵
    1. Stanley, S. E. and
    2. Armanios, M.
    (2015). The short and long telomere syndromes: paired paradigms for molecular medicine. Curr. Opin. Genet. Dev. 33, 1-9. doi:10.1016/j.gde.2015.06.004
    OpenUrlCrossRefPubMed
  152. ↵
    1. Stockklausner, C.,
    2. Raffel, S.,
    3. Klermund, J.,
    4. Bandapalli, O. R.,
    5. Beier, F.,
    6. Brümmendorf, T. H.,
    7. Bürger, F.,
    8. Sauer, S. W.,
    9. Hoffmann, G. F.,
    10. Lorenz, H. et al.
    (2015). A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition. Aging 7, 911-927. doi:10.18632/aging.100835
    OpenUrlCrossRefPubMed
  153. ↵
    1. Strandgren, C.,
    2. Nasser, H. A.,
    3. McKenna, T.,
    4. Koskela, A.,
    5. Tuukkanen, J.,
    6. Ohlsson, C.,
    7. Rozell, B. and
    8. Eriksson, M.
    (2015). Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects. FASEB J. 29, 3193-3205. doi:10.1096/fj.14-269217
    OpenUrlAbstract/FREE Full Text
  154. ↵
    1. Studer, L.,
    2. Vera, E. and
    3. Cornacchia, D.
    (2015). Programming and reprogramming cellular age in the era of induced pluripotency. Cell Stem Cell 16, 591-600. doi:10.1016/j.stem.2015.05.004
    OpenUrlCrossRefPubMed
  155. ↵
    1. Suzuki, N. M.,
    2. Niwa, A.,
    3. Yabe, M.,
    4. Hira, A.,
    5. Okada, C.,
    6. Amano, N.,
    7. Watanabe, A.,
    8. Watanabe, K.-I.,
    9. Heike, T.,
    10. Takata, M. et al.
    (2015). Pluripotent cell models of fanconi anemia identify the early pathological defect in human hemoangiogenic progenitors. Stem Cells Transl. Med. 4, 333-338. doi:10.5966/sctm.2013-0172
    OpenUrlAbstract/FREE Full Text
  156. ↵
    1. Tan, W.-H.,
    2. Baris, H.,
    3. Robson, C. D. and
    4. Kimonis, V. E.
    (2005). Cockayne syndrome: the developing phenotype. Am. J. Med. Genet. A 135A, 214-216. doi:10.1002/ajmg.a.30731
    OpenUrlCrossRefPubMed
  157. ↵
    1. Tang, S.,
    2. Xie, M.,
    3. Cao, N. and
    4. Ding, S.
    (2016). Patient-specific induced pluripotent stem cells for disease modeling and phenotypic drug discovery. J. Med. Chem. 59, 2-15. doi:10.1021/acs.jmedchem.5b00789
    OpenUrlCrossRefPubMed
    1. Thill, M.,
    2. Nguyen, T. D.,
    3. Wehnert, M.,
    4. Fischer, D.,
    5. Hausser, I.,
    6. Braun, S. and
    7. Jackisch, C.
    (2008). Restrictive dermopathy: a rare laminopathy. Arch. Gynecol. Obstet. 278, 201-208. doi:10.1007/s00404-008-0676-6
    OpenUrlCrossRefPubMed
  158. ↵
    1. Tilstra, J. S.,
    2. Robinson, A. R.,
    3. Wang, J.,
    4. Gregg, S. Q.,
    5. Clauson, C. L.,
    6. Reay, D. P.,
    7. Nasto, L. A.,
    8. St Croix, C. M.,
    9. Usas, A.,
    10. Vo, N. et al.
    (2012). NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J. Clin. Invest. 122, 2601-2612. doi:10.1172/JCI45785
    OpenUrlCrossRefPubMedWeb of Science
  159. ↵
    1. Tivey, H. S. E.,
    2. Rokicki, M. J.,
    3. Barnacle, J. R.,
    4. Rogers, M. J.,
    5. Bagley, M. C.,
    6. Kipling, D. and
    7. Davis, T.
    (2013). Small molecule inhibition of p38 MAP kinase extends the replicative life span of human ATR-Seckel syndrome fibroblasts. J. Gerontol. A Biol. Sci. Med. Sci. 68, 1001-1009. doi:10.1093/gerona/gls336
    OpenUrlAbstract/FREE Full Text
  160. ↵
    1. Ugalde, A. P.,
    2. Ramsay, A. J.,
    3. de la Rosa, J.,
    4. Varela, I.,
    5. Mariño, G.,
    6. Cadiñanos, J.,
    7. Lu, J.,
    8. Freije, J. M. P. and
    9. López-Otín, C.
    (2011). Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J. 30, 2219-2232. doi:10.1038/emboj.2011.124
    OpenUrlAbstract/FREE Full Text
  161. ↵
    1. Uziel, O.,
    2. Reshef, H.,
    3. Ravid, A.,
    4. Fabian, I.,
    5. Halperin, D.,
    6. Ram, R.,
    7. Bakhanashvili, M.,
    8. Nordenberg, J. and
    9. Lahav, M.
    (2008). Oxidative stress causes telomere damage in Fanconi anaemia cells - a possible predisposition for malignant transformation. Br. J. Haematol. 142, 82-93. doi:10.1111/j.1365-2141.2008.07137.x
    OpenUrlCrossRefPubMed
  162. ↵
    1. van der Pluijm, I.,
    2. Garinis, G. A.,
    3. Brandt, R. M. C.,
    4. Gorgels, T. G. M. F.,
    5. Wijnhoven, S. W.,
    6. Diderich, K. E. M.,
    7. de Wit, J.,
    8. Mitchell, J. R.,
    9. van Oostrom, C.,
    10. Beems, R. et al.
    (2007). Impaired genome maintenance suppresses the growth hormone--insulin-like growth factor 1 axis in mice with Cockayne syndrome. PLoS Biol. 5, e2. doi:10.1371/journal.pbio.0050002
    OpenUrlCrossRefPubMed
  163. ↵
    1. van Deursen, J. M.
    (2014). The role of senescent cells in ageing. Nature 509, 439-446. doi:10.1038/nature13193
    OpenUrlCrossRefPubMedWeb of Science
  164. ↵
    1. Vanhooren, V. and
    2. Libert, C.
    (2013). The mouse as a model organism in aging research: usefulness, pitfalls and possibilities. Ageing Res. Rev. 12, 8-21. doi:10.1016/j.arr.2012.03.010
    OpenUrlCrossRefPubMed
  165. ↵
    1. Varela, I.,
    2. Cadiñanos, J.,
    3. Pendás, A. M.,
    4. Gutiérrez-Fernández, A.,
    5. Folgueras, A. R.,
    6. Sánchez, L. M.,
    7. Zhou, Z.,
    8. Rodríguez, F. J.,
    9. Stewart, C. L.,
    10. Vega, J. A. et al.
    (2005). Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 437, 564-568. doi:10.1038/nature04019
    OpenUrlCrossRefPubMedWeb of Science
  166. ↵
    1. Varela, I.,
    2. Pereira, S.,
    3. Ugalde, A. P.,
    4. Navarro, C. L.,
    5. Suárez, M. F.,
    6. Cau, P.,
    7. Cadiñanos, J.,
    8. Osorio, F. G.,
    9. Foray, N.,
    10. Cobo, J. et al.
    (2008). Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14, 767-772. doi:10.1038/nm1786
    OpenUrlCrossRefPubMedWeb of Science
  167. ↵
    1. Varga, R.,
    2. Eriksson, M.,
    3. Erdos, M. R.,
    4. Olive, M.,
    5. Harten, I.,
    6. Kolodgie, F.,
    7. Capell, B. C.,
    8. Cheng, J.,
    9. Faddah, D.,
    10. Perkins, S. et al.
    (2006). Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA 103, 3250-3255. doi:10.1073/pnas.0600012103
    OpenUrlAbstract/FREE Full Text
  168. ↵
    1. Velez-Cruz, R.,
    2. Zadorin, A. S.,
    3. Coin, F. and
    4. Egly, J.-M.
    (2013). Sirt1 suppresses RNA synthesis after UV irradiation in combined xeroderma pigmentosum group D/Cockayne syndrome (XP-D/CS) cells. Proc. Natl. Acad. Sci. USA 110, E212-E220. doi:10.1073/pnas.1213076110
    OpenUrlAbstract/FREE Full Text
  169. ↵
    1. Vermeij, W. P.,
    2. Hoeijmakers, J. H. J. and
    3. Pothof, J.
    (2016). Genome integrity in aging: human syndromes, mouse models, and therapeutic options. Annu. Rev. Pharmacol. Toxicol. 56, 427-445. doi:10.1146/annurev-pharmtox-010814-124316
    OpenUrlCrossRefPubMed
  170. ↵
    1. Vijg, J. and
    2. Suh, Y.
    (2013). Genome instability and aging. Annu. Rev. Physiol. 75, 645-668. doi:10.1146/annurev-physiol-030212-183715
    OpenUrlCrossRefPubMedWeb of Science
  171. ↵
    1. Villa-Bellosta, R.,
    2. Rivera-Torres, J.,
    3. Osorio, F. G.,
    4. Acin-Perez, R.,
    5. Enriquez, J. A.,
    6. Lopez-Otin, C. and
    7. Andres, V.
    (2013). Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation 127, 2442-2451. doi:10.1161/CIRCULATIONAHA.112.000571
    OpenUrlAbstract/FREE Full Text
  172. ↵
    1. Walne, A. J.,
    2. Vulliamy, T.,
    3. Kirwan, M.,
    4. Plagnol, V. and
    5. Dokal, I.
    (2013). Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. Am. J. Hum. Genet. 92, 448-453. doi:10.1016/j.ajhg.2013.02.001
    OpenUrlCrossRefPubMed
  173. ↵
    1. Werner, S. R.,
    2. Prahalad, A. K.,
    3. Yang, J. and
    4. Hock, J. M.
    (2006). RECQL4-deficient cells are hypersensitive to oxidative stress/damage: insights for osteosarcoma prevalence and heterogeneity in Rothmund-Thomson syndrome. Biochem. Biophys. Res. Commun. 345, 403-409. doi:10.1016/j.bbrc.2006.04.093
    OpenUrlCrossRefPubMedWeb of Science
  174. ↵
    1. Wood, A. M.,
    2. Rendtlew Danielsen, J. M.,
    3. Lucas, C. A.,
    4. Rice, E. L.,
    5. Scalzo, D.,
    6. Shimi, T.,
    7. Goldman, R. D.,
    8. Smith, E. D.,
    9. Le Beau, M. M. and
    10. Kosak, S. T.
    (2014). TRF2 and lamin A/C interact to facilitate the functional organization of chromosome ends. Nat. Commun. 5, 5467. doi:10.1038/ncomms6467
    OpenUrlCrossRefPubMed
  175. ↵
    1. Xiong, Z.-M.,
    2. LaDana, C.,
    3. Wu, D. and
    4. Cao, K.
    (2013). An inhibitory role of progerin in the gene induction network of adipocyte differentiation from iPS cells. Aging 5, 288-303. doi:10.18632/aging.100550
    OpenUrlCrossRefPubMed
  176. ↵
    1. Xiong, Z.-M.,
    2. Choi, J. Y.,
    3. Wang, K.,
    4. Zhang, H.,
    5. Tariq, Z.,
    6. Wu, D.,
    7. Ko, E.,
    8. LaDana, C.,
    9. Sesaki, H. and
    10. Cao, K.
    (2016). Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria. Aging Cell 15, 279-290. doi:10.1111/acel.12434
    OpenUrlCrossRefPubMed
  177. ↵
    1. Yoon, A.,
    2. Peng, G.,
    3. Brandenburger, Y.,
    4. Zollo, O.,
    5. Xu, W.,
    6. Rego, E. and
    7. Ruggero, D.
    (2006). Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 312, 902-906. doi:10.1126/science.1123835
    OpenUrlAbstract/FREE Full Text
  178. ↵
    1. Yu, C.-E.,
    2. Oshima, J.,
    3. Fu, Y.-H.,
    4. Wijsman, E. M.,
    5. Hisama, F.,
    6. Alisch, R.,
    7. Matthews, S.,
    8. Nakura, J.,
    9. Miki, T.,
    10. Ouais, S. et al.
    (1996). Positional cloning of the Werner's syndrome gene. Science 272, 258-262. doi:10.1126/science.272.5259.258
    OpenUrlAbstract
  179. ↵
    1. Zhang, X.,
    2. Sejas, D. P.,
    3. Qiu, Y.,
    4. Williams, D. A. and
    5. Pang, Q.
    (2007). Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence. J. Cell Sci. 120, 1572-1583. doi:10.1242/jcs.003152
    OpenUrlAbstract/FREE Full Text
  180. ↵
    1. Zhang, Q.-S.,
    2. Marquez-Loza, L.,
    3. Eaton, L.,
    4. Duncan, A. W.,
    5. Goldman, D. C.,
    6. Anur, P.,
    7. Watanabe-Smith, K.,
    8. Rathbun, R. K.,
    9. Fleming, W. H.,
    10. Bagby, G. C. et al.
    (2010). Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol. Blood 116, 5140-5148. doi:10.1182/blood-2010-04-278226
    OpenUrlAbstract/FREE Full Text
    1. Zhang, J.,
    2. Lian, Q.,
    3. Zhu, G.,
    4. Zhou, F.,
    5. Sui, L.,
    6. Tan, C.,
    7. Mutalif, R. A.,
    8. Navasankari, R.,
    9. Zhang, Y.,
    10. Tse, H.-F. et al.
    (2011). A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 8, 31-45. doi:10.1016/j.stem.2010.12.002
    OpenUrlCrossRefPubMedWeb of Science
    1. Zhang, H.,
    2. Xiong, Z.-M. and
    3. Cao, K.
    (2014). Mechanisms controlling the smooth muscle cell death in progeria via down-regulation of poly(ADP-ribose) polymerase 1. Proc. Natl. Acad. Sci. USA 111, E2261-E2270. doi:10.1073/pnas.1320843111
    OpenUrlAbstract/FREE Full Text
  181. ↵
    1. Zhang, W.,
    2. Li, J.,
    3. Suzuki, K.,
    4. Qu, J.,
    5. Wang, P.,
    6. Zhou, J.,
    7. Liu, X.,
    8. Ren, R.,
    9. Xu, X.,
    10. Ocampo, A. et al.
    (2015). Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. Science 348, 1160-1163. doi:10.1126/science.aaa1356
    OpenUrlAbstract/FREE Full Text
  182. ↵
    1. Zlateska, B.,
    2. Ciccolini, A. and
    3. Dror, Y.
    (2015). Treatment of dyskeratosis congenita-associated pulmonary fibrosis with danazol. Pediatr. Pulmonol. 50, E48-E51. doi:10.1002/ppul.23235
    OpenUrlCrossRefPubMed
View Abstract
Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

RSSRSS

Keywords

  • Ageing
  • Progeria
  • Rejuvenation
  • iPSCs

 Download PDF

Email

Thank you for your interest in spreading the word on Disease Models & Mechanisms.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells
(Your Name) has sent you a message from Disease Models & Mechanisms
(Your Name) thought you would like to see the Disease Models & Mechanisms web site.
Share
Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells
Dido Carrero, Clara Soria-Valles, Carlos López-Otín
Disease Models & Mechanisms 2016 9: 719-735; doi: 10.1242/dmm.024711
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells
Dido Carrero, Clara Soria-Valles, Carlos López-Otín
Disease Models & Mechanisms 2016 9: 719-735; doi: 10.1242/dmm.024711

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • ABSTRACT
    • Introduction
    • A classification system for human progeroid syndromes
    • Cellular models of progeroid syndromes
    • Mouse models of progeroid syndromes
    • Hallmarks of progeroid syndromes
    • Therapeutic and rejuvenation strategies
    • Conclusions
    • Acknowledgements
    • Footnotes
    • References
  • Figures & tables
  • Info & metrics
  • PDF

Related articles

Cited by...

More in this TOC section

  • Metastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches
  • Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
  • Use of zebrafish to study Shigella infection
Show more REVIEW

Similar articles

Other journals from The Company of Biologists

Development

Journal of Cell Science

Journal of Experimental Biology

Biology Open

Advertisement

Editor’s Choice – Altered expression of the Cdk5 activator-like protein, Cdk5α, causes neurodegeneration, in part by accelerating the rate of aging

By developing a comprehensive and quantitative metric for physiological age of Drosophila, Edward Giniger and colleagues show that a neurodegeneration mutant produces its effects in part by accelerating the absolute rate of aging.


First Person interviews 

Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Sarah Foriel, Henna Myllymäki and Mirja Niskanen, Wenqing Zhou, Rifdat Aoidi and Amy Irving.


Review – Metastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches

In a new Review article, Jaap M. J. den Toonder and colleagues evaluate the recent contributions of cancer-on-a-chip models to our understanding of the tumor microenvironment and its role in the onset of metastasis. The authors also provide an outlook for future applications of this emerging technology.


DMM Conference Travel Grants

Are you an early career scientist with plans to attend a scientific meeting, conference, workshop or course relating to the areas of research covered by DMM? The next round of applications for DMM Conference Travel Grants closes on 4 May 2018. Find out more here and get your application in soon.


Why should you publish your next paper in DMM?

DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Subject collections
  • Interviews
  • Alerts

About us

  • About DMM
  • Editors and Board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Workshops and Meetings
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • Biology Open transfer

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Alerts

Contact

  • Contact DMM
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2018   The Company of Biologists Ltd   Registered Charity 277992